<?xml version="1.0"?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2015//EN" "http://www.ncbi.nlm.nih.gov/corehtml/query/DTD/pubmed_150101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">23523949</PMID>
        <DateCreated>
            <Year>2013</Year>
            <Month>05</Month>
            <Day>20</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2013</Year>
            <Month>07</Month>
            <Day>16</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1872-7786</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>203</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>May</Month>
                        <Day>25</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Chemico-biological interactions</Title>
                <ISOAbbreviation>Chem. Biol. Interact.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Protective effect of crocin on diazinon induced cardiotoxicity in rats in subchronic exposure.</ArticleTitle>
            <Pagination>
                <MedlinePgn>547-55</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cbi.2013.03.010</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">S0009-2797(13)00071-9</ELocationID>
            <Abstract>
                <AbstractText Label="UNLABELLED">This study was designed to evaluate the effectiveness of crocin, main component of Crocus sativus L. (Saffron) against subchronic diazinon (DZN) induced cardiotoxicity in rats.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Rats were divided into 7 groups; control (corn oil, gavage), DZN (15 mg/kg/day, gavage,), crocin (12.5, 25 or 50 mg/kg/day, i.p) plus DZN, vitamin E (200 IU/kg, i.p, three times per week) plus DZN and crocin (50 mg/kg/day, i.p) groups. Treatments were continued for 4 weeks. Creatine phosphokinase MB (CK-MB), malondealdehyde (MDA) and glutathione (GSH) levels were evaluated in heart tissue at the end of treatments. Levels of apoptotic proteins (Bax, Bcl2, caspase 3) and cytosolic cytochrome c were analyzed by Western blotting. Transcript levels of Bax and Bcl2 were also determined using qRT PCR.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">DZN induced histophatological damages and elevated the level of cardiac marker CK-MB. These effects were associated with increased MDA level, lower level of reduced GSH and induction of apoptosis through elevation of Bax/Bcl2 ratio (both protein and mRNA levels), cytochrome c release to the cytosol and activation caspase 3 in cardiac tissue. Crocin (25 and 50 mg/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax/Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN. In summary, DZN induced mitochondrial-mediated apoptosis in heart tissue of rat following subchronic exposure. Crocin, as an antioxidant, showed protective effects against DZN cardiotoxicity by reducing lipid peroxidation and alleviating apoptosis.</AbstractText>
                <CopyrightInformation>Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Razavi</LastName>
                    <ForeName>Bibi Marjan</ForeName>
                    <Initials>BM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacodynamy and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hosseinzadeh</LastName>
                    <ForeName>Hossein</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Movassaghi</LastName>
                    <ForeName>Ahmad Reza</ForeName>
                    <Initials>AR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Imenshahidi</LastName>
                    <ForeName>Mohsen</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Abnous</LastName>
                    <ForeName>Khalil</ForeName>
                    <Initials>K</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2013</Year>
                <Month>03</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Ireland</Country>
            <MedlineTA>Chem Biol Interact</MedlineTA>
            <NlmUniqueID>0227276</NlmUniqueID>
            <ISSNLinking>0009-2797</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C494828">Bax protein, rat</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007306">Insecticides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010936">Plant Extracts</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D051028">bcl-2-Associated X Protein</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>36-88-4</RegistryNumber>
                <NameOfSubstance UI="D002338">Carotenoids</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>42553-65-1</RegistryNumber>
                <NameOfSubstance UI="C029036">crocin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>4Y8F71G49Q</RegistryNumber>
                <NameOfSubstance UI="D008315">Malondialdehyde</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9007-43-6</RegistryNumber>
                <NameOfSubstance UI="D045304">Cytochromes c</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.3.2</RegistryNumber>
                <NameOfSubstance UI="D003402">Creatine Kinase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>GAN16C9B8O</RegistryNumber>
                <NameOfSubstance UI="D005978">Glutathione</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>YUS1M1Q929</RegistryNumber>
                <NameOfSubstance UI="D003976">Diazinon</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000975">Antioxidants</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002338">Carotenoids</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003402">Creatine Kinase</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D027622">Crocus</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D045304">Cytochromes c</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003976">Diazinon</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015870">Gene Expression</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005978">Glutathione</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006321">Heart</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006331">Heart Diseases</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007306">Insecticides</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008315">Malondialdehyde</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009206">Myocardium</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009336">Necrosis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000517">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018384">Oxidative Stress</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010936">Plant Extracts</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012333">RNA, Messenger</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017208">Rats, Wistar</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051028">bcl-2-Associated X Protein</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2012</Year>
                <Month>12</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2013</Year>
                <Month>2</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2013</Year>
                <Month>3</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2013</Year>
                <Month>3</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>3</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>3</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>7</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0009-2797(13)00071-9</ArticleId>
            <ArticleId IdType="doi">10.1016/j.cbi.2013.03.010</ArticleId>
            <ArticleId IdType="pubmed">23523949</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">20370541</PMID>
        <DateCreated>
            <Year>2010</Year>
            <Month>06</Month>
            <Day>24</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2010</Year>
            <Month>09</Month>
            <Day>30</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2015</Year>
            <Month>01</Month>
            <Day>17</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1029-2403</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>51</Volume>
                    <Issue>7</Issue>
                    <PubDate>
                        <Year>2010</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Leukemia &amp; lymphoma</Title>
                <ISOAbbreviation>Leuk. Lymphoma</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Expression profiles of adult T-cell leukemia-lymphoma and associations with clinical responses to zidovudine and interferon alpha.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1200-16</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.3109/10428191003728628</ELocationID>
            <Abstract>
                <AbstractText>Adult T-cell leukemia-lymphoma (ATLL) is an HTLV-1-associated lymphoproliferative malignancy that is frequently fatal. We compared gene expression profiles (GEPs) of leukemic specimens from nine patients with ATLL at the time of diagnosis and immediately after combination therapy with zidovudine (AZT) and interferon alpha (IFNalpha). GEPs were also related to genetic aberrations determined by comparative genomic hybridization. We identified several genes anomalously over-expressed in the ATLL leukemic cells at the mRNA level, including LYN, CSPG2, and LMO2, and confirmed LMO2 expression in ATLL cells at the protein level. In vivo AZT-IFNalpha therapy evoked a marked induction of interferon-induced genes accompanied by repression of cell-cycle regulated genes, including those encoding ribosomal proteins. Remarkably, patients not responding to AZT-IFNalpha differed most from responding patients in lower expression of these same IFN-responsive genes, as well as components of the antigen processing and presentation apparatus. Demonstration of specific gene expression signatures associated with response to AZT-IFNalpha therapy may provide novel insights into the mechanisms of action in ATLL.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Alizadeh</LastName>
                    <ForeName>Ash A</ForeName>
                    <Initials>AA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bohen</LastName>
                    <ForeName>Sean P</ForeName>
                    <Initials>SP</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lossos</LastName>
                    <ForeName>Chen</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Martinez-Climent</LastName>
                    <ForeName>Jose A</ForeName>
                    <Initials>JA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ramos</LastName>
                    <ForeName>Juan Carlos</ForeName>
                    <Initials>JC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cubedo-Gil</LastName>
                    <ForeName>Elena</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Harrington</LastName>
                    <ForeName>William J</ForeName>
                    <Initials>WJ</Initials>
                    <Suffix>Jr</Suffix>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lossos</LastName>
                    <ForeName>Izidore S</ForeName>
                    <Initials>IS</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>P30 CA124435</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 CA109335</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 CA109335</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 CA122105</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Leuk Lymphoma</MedlineTA>
            <NlmUniqueID>9007422</NlmUniqueID>
            <ISSNLinking>1026-8022</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D019380">Anti-HIV Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014408">Tumor Markers, Biological</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>4B9XT59T7S</RegistryNumber>
                <NameOfSubstance UI="D015215">Zidovudine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Leuk Lymphoma. 2010 Jul;51(7):1157-8</RefSource>
                <PMID Version="1">20388057</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019380">Anti-HIV Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D055028">Comparative Genomic Hybridization</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D020869">Gene Expression Profiling</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016898">Interferon-alpha</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020411">Oligonucleotide Array Sequence Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012333">RNA, Messenger</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020133">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014408">Tumor Markers, Biological</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015215">Zidovudine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">NIHMS636985</OtherID>
        <OtherID Source="NLM">PMC4296320</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2010</Year>
                <Month>4</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2010</Year>
                <Month>4</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2010</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.3109/10428191003728628</ArticleId>
            <ArticleId IdType="pubmed">20370541</ArticleId>
            <ArticleId IdType="pmc">PMC4296320</ArticleId>
            <ArticleId IdType="mid">NIHMS636985</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">18692086</PMID>
        <DateCreated>
            <Year>2008</Year>
            <Month>12</Month>
            <Day>19</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>04</Month>
            <Day>02</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">0091-3057</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>91</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Jan</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Pharmacology, biochemistry, and behavior</Title>
                <ISOAbbreviation>Pharmacol. Biochem. Behav.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Antidepressant activity of Asparagus racemosus in rodent models.</ArticleTitle>
            <Pagination>
                <MedlinePgn>283-90</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pbb.2008.07.010</ELocationID>
            <Abstract>
                <AbstractText>Asparagus racemosus Linn. (AR) is an Ayurvedic rasayana used as an adaptogen. Adaptogenic drugs are those which are useful as anti-stress agents by promoting non-specific resistance of the body. Although, the adaptogenic effect of AR is well documented, its use in psychological disorders like depression is not scientifically evaluated. Hence, the present investigation evaluates the antidepressant effect of methanolic extract of roots of AR (MAR) standardized to saponins (62.2% w/w). Rats were given MAR in the doses of 100, 200 and 400 mg/kg daily for 7 days and then subjected to forced swim test (FST) and learned helplessness test (LH). The results show that MAR decreases immobility in FST and increases avoidance response in LH indicating antidepressant activity. In behavioral experiments, MAR increased the number of head twitches produced by 5-HTP and increased clonidine-induced aggressive behavior indicating facilitatory effect on both serotonergic and adrenergic systems respectively. However, MAR had insignificant effect on l-DOPA-induced aggressive behavior indicating absence of activity on dopaminergic system. MAR also reversed changes to the endogenous antioxidant system induced by FST. Thus, MAR has significant antidepressant activity and this effect is probably mediated through the serotonergic and the noradrenergic systems and augmentation of antioxidant defenses.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Singh</LastName>
                    <ForeName>Gireesh K</ForeName>
                    <Initials>GK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Pharmacology Division, Department of Pharmaceutics, Institute of Technology, Banaras Hindu University, Varanasi-221005, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Garabadu</LastName>
                    <ForeName>Debapriya</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Muruganandam</LastName>
                    <ForeName>A V</ForeName>
                    <Initials>AV</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Joshi</LastName>
                    <ForeName>Vinod K</ForeName>
                    <Initials>VK</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Krishnamurthy</LastName>
                    <ForeName>Sairam</ForeName>
                    <Initials>S</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2008</Year>
                <Month>07</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Pharmacol Biochem Behav</MedlineTA>
            <NlmUniqueID>0367050</NlmUniqueID>
            <ISSNLinking>0091-3057</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000316">Adrenergic alpha-Agonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D015259">Dopamine Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010936">Plant Extracts</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>46627O600J</RegistryNumber>
                <NameOfSubstance UI="D007980">Levodopa</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>C1LJO185Q9</RegistryNumber>
                <NameOfSubstance UI="D006916">5-Hydroxytryptophan</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.15.1.1</RegistryNumber>
                <NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>MN3L5RMN02</RegistryNumber>
                <NameOfSubstance UI="D003000">Clonidine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006916">5-Hydroxytryptophan</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000316">Adrenergic alpha-Agonists</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000374">Aggression</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000928">Antidepressive Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000975">Antioxidants</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D027761">Asparagus Plant</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003000">Clonidine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015259">Dopamine Agents</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019416">Head Movements</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006380">Helplessness, Learned</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006624">Hippocampus</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006948">Hyperkinesis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015227">Lipid Peroxidation</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008515">Medicine, Ayurvedic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017072">Neostriatum</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010936">Plant Extracts</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018517">Plant Roots</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013482">Superoxide Dismutase</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013550">Swimming</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2007</Year>
                <Month>12</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2008</Year>
                <Month>7</Month>
                <Day>8</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2008</Year>
                <Month>7</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2008</Year>
                <Month>7</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2008</Year>
                <Month>8</Month>
                <Day>12</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>4</Month>
                <Day>3</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2008</Year>
                <Month>8</Month>
                <Day>12</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0091-3057(08)00265-7</ArticleId>
            <ArticleId IdType="doi">10.1016/j.pbb.2008.07.010</ArticleId>
            <ArticleId IdType="pubmed">18692086</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">6251483</PMID>
        <DateCreated>
            <Year>1980</Year>
            <Month>11</Month>
            <Day>24</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1980</Year>
            <Month>11</Month>
            <Day>24</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0091-3057</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>13</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>1980</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Pharmacology, biochemistry, and behavior</Title>
                <ISOAbbreviation>Pharmacol. Biochem. Behav.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Effects of chronic administration of antidepressant drugs on aggressive behavior induced by clonidine in mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>153-4</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>The effects of antidepressant drugs on clonidine-induced aggressive behavior were determined in mice. Imipramine, mianserin and iprindole used in a single dose attenuated clonidine-induced aggression. Their chronic administration enhanced it.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Maj</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mogilnicka</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kordecka-Magiera</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Pharmacol Biochem Behav</MedlineTA>
            <NlmUniqueID>0367050</NlmUniqueID>
            <ISSNLinking>0091-3057</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017981">Receptors, Neurotransmitter</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>MN3L5RMN02</RegistryNumber>
                <NameOfSubstance UI="D003000">Clonidine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000374">Aggression</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000928">Antidepressive Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003000">Clonidine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004347">Drug Interactions</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017981">Receptors, Neurotransmitter</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1980</Year>
                <Month>8</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1980</Year>
                <Month>8</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1980</Year>
                <Month>8</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">6251483</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">2522633</PMID>
        <DateCreated>
            <Year>1989</Year>
            <Month>04</Month>
            <Day>25</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1989</Year>
            <Month>04</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2004</Year>
            <Month>11</Month>
            <Day>17</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0755-4982</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>18</Volume>
                    <Issue>7</Issue>
                    <PubDate>
                        <Year>1989</Year>
                        <Month>Feb</Month>
                        <Day>18</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Presse médicale (Paris, France : 1983)</Title>
                <ISOAbbreviation>Presse Med</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[Multiple thrombosis and thrombocytopenia due to heparin occurring after plasma exchange].</ArticleTitle>
            <Pagination>
                <MedlinePgn>359</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Fourrier</LastName>
                    <ForeName>F</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Marey</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Muller</LastName>
                    <ForeName>J P</ForeName>
                    <Initials>JP</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lestavel</LastName>
                    <ForeName>P</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Goudemand</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chopin</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                </Author>
            </AuthorList>
            <Language>fre</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016422">Letter</PublicationType>
            </PublicationTypeList>
            <VernacularTitle>Thromboses multiples et thrombopénie à l'héparine survenant après échanges plasmatiques.</VernacularTitle>
        </Article>
        <MedlineJournalInfo>
            <Country>FRANCE</Country>
            <MedlineTA>Presse Med</MedlineTA>
            <NlmUniqueID>8302490</NlmUniqueID>
            <ISSNLinking>0755-4982</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9005-49-6</RegistryNumber>
                <NameOfSubstance UI="D006493">Heparin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006493">Heparin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007074">Immunoglobulin G</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010951">Plasma Exchange</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013921">Thrombocytopenia</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1989</Year>
                <Month>2</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1989</Year>
                <Month>2</Month>
                <Day>18</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1989</Year>
                <Month>2</Month>
                <Day>18</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2522633</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
        <PMID Version="1">25710175</PMID>
        <DateCreated>
            <Year>2015</Year>
            <Month>02</Month>
            <Day>25</Day>
        </DateCreated>
        <DateRevised>
            <Year>2015</Year>
            <Month>03</Month>
            <Day>05</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>10</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2015</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Gene expression in obliterative bronchiolitis-like lesions in 2,3-pentanedione-exposed rats.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e0118459</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0118459</ELocationID>
            <Abstract>
                <AbstractText>Obliterative bronchiolitis (OB) is an irreversible lung disease characterized by progressive fibrosis in the small airways with eventual occlusion of the airway lumens. OB is most commonly associated with lung transplant rejection; however, OB has also been diagnosed in workers exposed to artificial butter flavoring (ABF) vapors. Research has been limited by the lack of an adequate animal model of OB, and as a result the mechanism(s) is unclear and there are no effective treatments for this condition. Exposure of rats to the ABF component, 2,3-pentanedione (PD) results in airway lesions that are histopathologically similar to those in human OB. We used this animal model to evaluate changes in gene expression in the distal bronchi of rats with PD-induced OB. Male Wistar Han rats were exposed to 200 ppm PD or air 6 h/d, 5 d/wk for 2-wks. Bronchial tissues were laser microdissected from serial sections of frozen lung. In exposed lungs, both fibrotic and non-fibrotic airways were collected. Following RNA extraction and microarray analysis, differential gene expression was evaluated. In non-fibrotic bronchi of exposed rats, 4683 genes were significantly altered relative to air-exposed controls with notable down-regulation of many inflammatory cytokines and chemokines. In contrast, in fibrotic bronchi, 3807 genes were significantly altered with a majority of genes being up-regulated in affected pathways. Tgf-β2 and downstream genes implicated in fibrosis were significantly up-regulated in fibrotic lesions. Genes for collagens and extracellular matrix proteins were highly up-regulated. In addition, expression of genes for peptidases and peptidase inhibitors were significantly altered, indicative of the tissue remodeling that occurs during airway fibrosis. Our data provide new insights into the molecular mechanisms of OB. This new information is of potential significance with regard to future therapeutic targets for treatment.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Morgan</LastName>
                    <ForeName>Daniel L</ForeName>
                    <Initials>DL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of the National Toxicology Program, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, United States of America.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Merrick</LastName>
                    <ForeName>B Alex</ForeName>
                    <Initials>BA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of the National Toxicology Program, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, United States of America.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gerrish</LastName>
                    <ForeName>Kevin E</ForeName>
                    <Initials>KE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Intramural Research, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, United States of America.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stockton</LastName>
                    <ForeName>Patricia S</ForeName>
                    <Initials>PS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of the National Toxicology Program, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, United States of America.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Yu</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of the National Toxicology Program, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, United States of America.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Foley</LastName>
                    <ForeName>Julie F</ForeName>
                    <Initials>JF</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of the National Toxicology Program, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, United States of America.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gwinn</LastName>
                    <ForeName>William M</ForeName>
                    <Initials>WM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of the National Toxicology Program, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, United States of America.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kelly</LastName>
                    <ForeName>Francine L</ForeName>
                    <Initials>FL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Duke University Medical Center, Durham, North Carolina, United States of America.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Palmer</LastName>
                    <ForeName>Scott M</ForeName>
                    <Initials>SM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Duke University Medical Center, Durham, North Carolina, United States of America.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ton</LastName>
                    <ForeName>Thai-Vu T</ForeName>
                    <Initials>TV</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of the National Toxicology Program, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, United States of America.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Flake</LastName>
                    <ForeName>Gordon P</ForeName>
                    <Initials>GP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of the National Toxicology Program, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, United States of America.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2015</Year>
                <Month>02</Month>
                <Day>24</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Physiol Lung Cell Mol Physiol. 2012 Jan 15;302(2):L193-205</RefSource>
                <PMID Version="1">22003091</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Chest. 1992 Jun;101(6):1663-73</RefSource>
                <PMID Version="1">1534744</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Interferon Cytokine Res. 2012 Oct;32(10):443-9</RefSource>
                <PMID Version="1">22900713</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Annu Rev Physiol. 2013;75:551-67</RefSource>
                <PMID Version="1">23072447</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Respirology. 2013 May;18(4):643-51</RefSource>
                <PMID Version="1">23253121</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Scand Cardiovasc J. 1998;32(2):97-103</RefSource>
                <PMID Version="1">9636965</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Physiol. 1998 Jun;274(6 Pt 1):L1049-57</RefSource>
                <PMID Version="1">9609745</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Cancer Res. 1998 Jul;4(7):1785-8</RefSource>
                <PMID Version="1">9676856</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem Biophys Res Commun. 1998 Sep 8;250(1):119-24</RefSource>
                <PMID Version="1">9735343</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Cancer. 1999 Jan;79(2):354-9</RefSource>
                <PMID Version="1">9888480</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Heart Lung Transplant. 1999 Sep;18(9):828-37</RefSource>
                <PMID Version="1">10528744</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Allergy Clin Immunol. 2005 Jan;115(1):110-7</RefSource>
                <PMID Version="1">15637555</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur Respir J. 2005 Mar;25(3):494-501</RefSource>
                <PMID Version="1">15738294</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Transplant. 2005 Apr;5(4 Pt 1):671-83</RefSource>
                <PMID Version="1">15760390</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Immunity. 2005 Nov;23(5):479-90</RefSource>
                <PMID Version="1">16286016</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bioinformatics. 2006 May 1;22(9):1111-21</RefSource>
                <PMID Version="1">16522673</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Physiol Lung Cell Mol Physiol. 2006 Dec;291(6):L1277-85</RefSource>
                <PMID Version="1">16891397</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Crit Care. 2007;11(1):R8</RefSource>
                <PMID Version="1">17241453</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Biochem Cell Biol. 2008;40(3):484-95</RefSource>
                <PMID Version="1">17931953</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Heart Lung Transplant. 2008 Apr;27(4):400-7</RefSource>
                <PMID Version="1">18374876</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochim Biophys Acta. 2008 Sep;1781(9):513-8</RefSource>
                <PMID Version="1">18621144</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Perinatol. 2008 Dec;28 Suppl 3:S127-35</RefSource>
                <PMID Version="1">19057604</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Oncol. 2009 Jan;34(1):5-13</RefSource>
                <PMID Version="1">19082472</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Clin Pathol. 2009 May;131(5):738-43</RefSource>
                <PMID Version="1">19369636</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2009 Jun 2;106(22):9021-6</RefSource>
                <PMID Version="1">19439663</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Transplant. 2009 Sep;9(9):1981-7</RefSource>
                <PMID Version="1">19663891</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Respir Cell Mol Biol. 2009 Dec;41(6):661-70</RefSource>
                <PMID Version="1">19265174</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem Biophys Res Commun. 2010 Feb 19;392(4):495-9</RefSource>
                <PMID Version="1">20093106</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cytokine. 2011 Jan;53(1):19-28</RefSource>
                <PMID Version="1">21050772</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Physiol Lung Cell Mol Physiol. 2010 Dec;299(6):L785-93</RefSource>
                <PMID Version="1">20833777</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Curr Opin Immunol. 2010 Dec;22(6):800-6</RefSource>
                <PMID Version="1">21071194</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>FASEB J. 2000 Jul;14(10):1362-74</RefSource>
                <PMID Version="1">10877829</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1778-83</RefSource>
                <PMID Version="1">10677534</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS One. 2011;6(3):e17644</RefSource>
                <PMID Version="1">21464978</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Transplantation. 2000 Jul 27;70(2):362-7</RefSource>
                <PMID Version="1">10933164</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Matrix Biol. 2000 Dec;19(7):557-68</RefSource>
                <PMID Version="1">11102746</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Histochem Cytochem. 2001 Feb;49(2):237-46</RefSource>
                <PMID Version="1">11156692</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Virchows Arch. 2001 Jul;439(1):78-84</RefSource>
                <PMID Version="1">11499844</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Heart Lung Transplant. 2001 Nov;20(11):1144-51</RefSource>
                <PMID Version="1">11704473</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Crit Rev Oral Biol Med. 1997;8(2):217-36</RefSource>
                <PMID Version="1">9167094</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Respir Crit Care Med. 1997 Sep;156(3 Pt 1):951-8</RefSource>
                <PMID Version="1">9310019</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Respir Res. 2011;12:48</RefSource>
                <PMID Version="1">21496259</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Transpl Int. 2011 Oct;24(10):1027-39</RefSource>
                <PMID Version="1">21797940</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Growth Factors. 2011 Oct;29(5):196-202</RefSource>
                <PMID Version="1">21740331</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cold Spring Harb Perspect Biol. 2011 Oct;3(10):a009712</RefSource>
                <PMID Version="1">21875984</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nucleic Acids Res. 2002 Jan 1;30(1):207-10</RefSource>
                <PMID Version="1">11752295</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):6292-7</RefSource>
                <PMID Version="1">11983918</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2002 Aug 1;347(5):330-8</RefSource>
                <PMID Version="1">12151470</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2002 Dec 12;420(6916):636-42</RefSource>
                <PMID Version="1">12478285</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Cell Sci. 2003 Jan 15;116(Pt 2):217-24</RefSource>
                <PMID Version="1">12482908</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Respir Cell Mol Biol. 2003 Feb;28(2):142-9</RefSource>
                <PMID Version="1">12540481</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Oncol Rep. 2003 Jul-Aug;10(4):881-4</RefSource>
                <PMID Version="1">12792739</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cytokine Growth Factor Rev. 2003 Dec;14(6):479-88</RefSource>
                <PMID Version="1">14563350</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Respir Crit Care Med. 2003 Dec 1;168(11):1277-92</RefSource>
                <PMID Version="1">14644923</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Heart Lung Transplant. 2004 Apr;23(4):446-55</RefSource>
                <PMID Version="1">15063404</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Immunol. 1982 May;128(5):2177-82</RefSource>
                <PMID Version="1">6460819</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Cell Biol. 1983 Dec;97(6):1925-32</RefSource>
                <PMID Version="1">6358238</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arthritis Rheum. 1984 Sep;27(9):995-1001</RefSource>
                <PMID Version="1">6332633</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Immunol. 1985 Feb;134(2):904-9</RefSource>
                <PMID Version="1">3871221</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem J. 1987 Nov 1;247(3):597-604</RefSource>
                <PMID Version="1">3501287</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 1988 Apr 5;263(10):4586-92</RefSource>
                <PMID Version="1">2965146</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Commun. 2012;3:735</RefSource>
                <PMID Version="1">22415826</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <OtherID Source="NLM">PMC4339611</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2015</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>8</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2015</Year>
                <Month>1</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2015</Year>
                <Month>2</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2015</Year>
                <Month>2</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2015</Year>
                <Month>2</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2015</Year>
                <Month>2</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0118459</ArticleId>
            <ArticleId IdType="pii">PONE-D-13-33746</ArticleId>
            <ArticleId IdType="pubmed">25710175</ArticleId>
            <ArticleId IdType="pmc">PMC4339611</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">18692083</PMID>
        <DateCreated>
            <Year>2008</Year>
            <Month>10</Month>
            <Day>16</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2008</Year>
            <Month>11</Month>
            <Day>06</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>09</Month>
            <Day>05</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1096-0333</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>232</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2008</Year>
                        <Month>Oct</Month>
                        <Day>15</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Toxicology and applied pharmacology</Title>
                <ISOAbbreviation>Toxicol. Appl. Pharmacol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Characterization of biliary conjugates of 4,4'-methylenedianiline in male versus female rats.</ArticleTitle>
            <Pagination>
                <MedlinePgn>190-202</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.taap.2008.06.008</ELocationID>
            <Abstract>
                <AbstractText>4,4'-Methylenedianiline (4,4'-diaminodiphenylmethane; DAPM) is an aromatic diamine used in the production of numerous polyurethane foams and epoxy resins. Previous studies in rats revealed that DAPM initially injures biliary epithelial cells of the liver, that the toxicity is greater in female than in male rats, and that the toxic metabolites of DAPM are excreted into bile. Since male and female rats exhibit differences in the expression of both phase I and phase II enzymes, our hypothesis was that female rats either metabolize DAPM to more toxic metabolites or have a decreased capacity to conjugate metabolites to less toxic intermediates. Our objective was thus to isolate, characterize, and quantify DAPM metabolites excreted into bile in both male and female bile duct-cannulated Sprague Dawley rats. The rats were gavaged with [(14)C]-DAPM, and the collected bile was subjected to reversed-phase HPLC with radioisotope detection. Peaks eluting from HPLC were collected and analyzed using electrospray MS and NMR spectroscopy. HPLC analysis indicated numerous metabolites in both sexes, but male rats excreted greater amounts of glutathione and glucuronide conjugates than females. Electrospray MS and NMR spectra of HPLC fractions revealed that the most prominent metabolite found in bile of both sexes was a glutathione conjugate of an imine metabolite of a 4'-nitroso-DAPM. Seven other metabolites were identified, including acetylated, cysteinyl-glycine, glutamyl-cysteine, glycine, and glucuronide conjugates. While our prior studies demonstrated increased covalent binding of DAPM in the liver and bile of female compared to male rats, in these studies, SDS-PAGE with autoradiography revealed 4-5 radiolabeled protein bands in the bile of rats treated with [(14)C]-DAPM. In addition, these bands were much more prominent in female than in male rats. These studies thus suggest that a plausible mechanism for the increased sensitivity of female rats to DAPM toxicity may be decreased conjugation of reactive DAPM metabolites, leading to greater levels of protein adduct formation.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Kan</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Chemistry, University of New Orleans, New Orleans, LA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cole</LastName>
                    <ForeName>Richard B</ForeName>
                    <Initials>RB</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Santa Cruz</LastName>
                    <ForeName>Vicente</ForeName>
                    <Initials>V</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Blakeney</LastName>
                    <ForeName>Ernest W</ForeName>
                    <Initials>EW</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kanz</LastName>
                    <ForeName>Mary F</ForeName>
                    <Initials>MF</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dugas</LastName>
                    <ForeName>Tammy R</ForeName>
                    <Initials>TR</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>1F32 ES05892</GrantID>
                    <Acronym>ES</Acronym>
                    <Agency>NIEHS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>ES06348</GrantID>
                    <Acronym>ES</Acronym>
                    <Agency>NIEHS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>F32 ES005892</GrantID>
                    <Acronym>ES</Acronym>
                    <Agency>NIEHS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>F32 ES005892-01</GrantID>
                    <Acronym>ES</Acronym>
                    <Agency>NIEHS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 ES006348-03</GrantID>
                    <Acronym>ES</Acronym>
                    <Agency>NIEHS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>T32 ES007254-09</GrantID>
                    <Acronym>ES</Acronym>
                    <Agency>NIEHS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>T32 ES07254</GrantID>
                    <Acronym>ES</Acronym>
                    <Agency>NIEHS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
                <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2008</Year>
                <Month>07</Month>
                <Day>01</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Toxicol Appl Pharmacol</MedlineTA>
            <NlmUniqueID>0416575</NlmUniqueID>
            <ISSNLinking>0041-008X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000485">Allergens</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>GG5LL7OBZC</RegistryNumber>
                <NameOfSubstance UI="C009505">4,4'-diaminodiphenylmethane</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Ind Med. 1986 Sep;43(9):620-5</RefSource>
                <PMID Version="1">3756114</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Toxicol Environ Health. 1986;18(3):325-37</RefSource>
                <PMID Version="1">3712494</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacol Toxicol. 1988 May;62(5):250-8</RefSource>
                <PMID Version="1">3413026</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacol Ther. 1988;38(3):269-304</RefSource>
                <PMID Version="1">3057513</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biomed Environ Mass Spectrom. 1988 Sep;17(3):161-7</RefSource>
                <PMID Version="1">3214672</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 1990 Sep 13;347(6289):203-6</RefSource>
                <PMID Version="1">2203971</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Anal Biochem. 1990 Nov 1;190(2):175-81</RefSource>
                <PMID Version="1">2291463</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 1992 Feb 25;267(6):3915-21</RefSource>
                <PMID Version="1">1740439</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Chem Biol Interact. 1992 Apr 15;82(2):151-63</RefSource>
                <PMID Version="1">1568267</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Appl Pharmacol. 1992 Nov;117(1):88-97</RefSource>
                <PMID Version="1">1440618</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem J. 1993 Aug 15;294 ( Pt 1):159-65</RefSource>
                <PMID Version="1">8363567</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Drug Metab Rev. 1994;26(1-2):413-29</RefSource>
                <PMID Version="1">8082577</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Occup Environ Med. 1994 Aug;51(8):519-22</RefSource>
                <PMID Version="1">7951775</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Lett. 1995 Jul;78(2):165-71</RefSource>
                <PMID Version="1">7618181</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem Pharmacol. 1996 May 3;51(9):1195-202</RefSource>
                <PMID Version="1">8645343</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Drug Metab Dispos. 1996 Jan;24(1):28-33</RefSource>
                <PMID Version="1">8825187</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Chem Res Toxicol. 1998 Jun;11(6):614-21</RefSource>
                <PMID Version="1">9625729</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Appl Pharmacol. 1998 Jun;150(2):414-26</RefSource>
                <PMID Version="1">9653073</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Drug Metab Rev. 1998 Aug;30(3):441-98</RefSource>
                <PMID Version="1">9710703</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Drug Metab Dispos. 1999 Sep;27(9):1045-56</RefSource>
                <PMID Version="1">10460805</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Mass Spectrom. 2006 Jun;41(6):728-34</RefSource>
                <PMID Version="1">16685702</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2006 Sep 15;281(37):26785-91</RefSource>
                <PMID Version="1">16857674</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Toxicol Environ Health A. 2001 Mar 23;62(6):467-83</RefSource>
                <PMID Version="1">11289319</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Anal Chem. 2001 Aug 1;73(15):430A-439A</RefSource>
                <PMID Version="1">11510863</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Sci. 2003 Aug;74(2):447-56</RefSource>
                <PMID Version="1">12773769</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Nutr. 2004 Mar;134(3):489-92</RefSource>
                <PMID Version="1">14988435</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 1974 Aug 8;291(6):278-82</RefSource>
                <PMID Version="1">4407276</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem J. 1977 Mar 15;162(3):545-56</RefSource>
                <PMID Version="1">869904</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>JAMA. 1979 Oct 5;242(14):1527-8</RefSource>
                <PMID Version="1">470092</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Chem Biol Interact. 1982 Mar 1;39(1):111-27</RefSource>
                <PMID Version="1">7060218</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Gan. 1981 Dec;72(6):937-43</RefSource>
                <PMID Version="1">6804295</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Carcinogenesis. 1983;4(4):467-72</RefSource>
                <PMID Version="1">6132685</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Drug Metab Dispos. 1983 Mar-Apr;11(2):109-14</RefSource>
                <PMID Version="1">6133713</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacol Rev. 1984 Mar;36(1):1-67</RefSource>
                <PMID Version="1">6144113</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Natl Cancer Inst. 1984 Jun;72(6):1457-63</RefSource>
                <PMID Version="1">6587162</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Med J Aust. 1984 Oct 13;141(8):533-5</RefSource>
                <PMID Version="1">6482804</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Anal Toxicol. 1988 Jan-Feb;12(1):9-14</RefSource>
                <PMID Version="1">3352246</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000485">Allergens</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000814">Aniline Compounds</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001659">Biliary Tract</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017207">Rats, Sprague-Dawley</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D012727">Sex Characteristics</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">NIHMS73620</OtherID>
        <OtherID Source="NLM">PMC2614345</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2008</Year>
                <Month>5</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2008</Year>
                <Month>6</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2008</Year>
                <Month>7</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2008</Year>
                <Month>8</Month>
                <Day>12</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2008</Year>
                <Month>11</Month>
                <Day>7</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2008</Year>
                <Month>8</Month>
                <Day>12</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0041-008X(08)00263-9</ArticleId>
            <ArticleId IdType="doi">10.1016/j.taap.2008.06.008</ArticleId>
            <ArticleId IdType="pubmed">18692083</ArticleId>
            <ArticleId IdType="pmc">PMC2614345</ArticleId>
            <ArticleId IdType="mid">NIHMS73620</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">1052090</PMID>
        <DateCreated>
            <Year>1977</Year>
            <Month>03</Month>
            <Day>21</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1977</Year>
            <Month>03</Month>
            <Day>21</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0091-2174</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>7</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <MedlineDate>1976-1977</MedlineDate>
                    </PubDate>
                </JournalIssue>
                <Title>International journal of psychiatry in medicine</Title>
                <ISOAbbreviation>Int J Psychiatry Med</ISOAbbreviation>
            </Journal>
            <ArticleTitle>An unusual adverse reaction to self-medication with prednisone: an irrational crime during a fugue-state.</ArticleTitle>
            <Pagination>
                <MedlinePgn>97-122</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>During five years of self-medication with Prednisone, a forty-one-year old asthmatic businessman experienced periods of euphoria, psychomotor hyperactivity, and poor judgement; a period of depression and anxiety during temporary steroid withdrawal; and finally, with resumption of Prednisone, episodes of grandiosity and bizarre fugue-like behavior, with adoption of a second identity and culminating in an irrational crime. Steroids were then withdrawn, and the patient resumed his premorbid personality, but had amnesia for much of his previous behavior. The literature on hysterical fugues and corticosteroid-induced mental disturbance is reviewed. The patient's reactions are analyzed in terms of his premorbid neurotic conflicts, the psychological stresses acting upon him, and the effects of Prednisone on his central nervous system.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Gifford</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Murawski</LastName>
                    <ForeName>B J</ForeName>
                    <Initials>BJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kline</LastName>
                    <ForeName>N S</ForeName>
                    <Initials>NS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sachar</LastName>
                    <ForeName>E J</ForeName>
                    <Initials>EJ</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Int J Psychiatry Med</MedlineTA>
            <NlmUniqueID>0365646</NlmUniqueID>
            <ISSNLinking>0091-2174</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>VB0R961HZT</RegistryNumber>
                <NameOfSubstance UI="D011241">Prednisone</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000647">Amnesia</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001249">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002490">Central Nervous System</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003220">Conflict (Psychology)</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D003417">Criminal Psychology</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004213">Dissociative Disorders</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005059">Euphoria</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005201">Fantasy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007063">Identity Crisis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009043">Motor Activity</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010551">Personality</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011241">Prednisone</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012651">Self Medication</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013315">Stress, Psychological</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013375">Substance Withdrawal Syndrome</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1976</Year>
                <Month>1</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1976</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1976</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">1052090</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">8969033</PMID>
        <DateCreated>
            <Year>1997</Year>
            <Month>03</Month>
            <Day>20</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1997</Year>
            <Month>03</Month>
            <Day>20</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0730-2347</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>23</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>1996</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Texas Heart Institute journal / from the Texas Heart Institute of St. Luke's Episcopal Hospital, Texas Children's Hospital</Title>
                <ISOAbbreviation>Tex Heart Inst J</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Ketanserin in the treatment of protamine-induced pulmonary hypertension.</ArticleTitle>
            <Pagination>
                <MedlinePgn>301-4</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>The reversal of heparin by protamine may cause severe hemodynamic deterioration, characterized by systemic hypotension, pulmonary hypertension, and bronchoconstriction. A case report is presented concerning the administration of ketanserin in the treatment of pulmonary vasoconstriction and right ventricular failure following the infusion of protamine in a patient undergoing coronary artery bypass surgery and mitral valve replacement. The potential role of serotonin in the development of this serious complication is discussed.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>van der Starre</LastName>
                    <ForeName>P J</ForeName>
                    <Initials>PJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cardiothoracic Anesthesiology and Intensive Care Hospital De Weezenlanden, Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Solinas</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Tex Heart Inst J</MedlineTA>
            <NlmUniqueID>8214622</NlmUniqueID>
            <ISSNLinking>0730-2347</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D006494">Heparin Antagonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011479">Protamines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012702">Serotonin Antagonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>97F9DE4CT4</RegistryNumber>
                <NameOfSubstance UI="D007650">Ketanserin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Acta Anaesthesiol Scand. 1972;16(2):76-84</RefSource>
                <PMID Version="1">5073205</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Cardiothorac Anesth. 1988 Apr;2(2):225-42</RefSource>
                <PMID Version="1">17171918</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Anesthesiology. 1983 Nov;59(5):470-3</RefSource>
                <PMID Version="1">6638558</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Anaesth. 1984 Apr;56(4):339-43</RefSource>
                <PMID Version="1">6608952</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Can Anaesth Soc J. 1985 Jan;32(1):49-52</RefSource>
                <PMID Version="1">3971203</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Can Anaesth Soc J. 1985 Jan;32(1):5-11</RefSource>
                <PMID Version="1">3971204</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Anesth Analg. 1985 Mar;64(3):348-61</RefSource>
                <PMID Version="1">3883848</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Thorac Cardiovasc Surg. 1985 Jul;90(1):86-90</RefSource>
                <PMID Version="1">3892171</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Anesth Analg. 1986 Jan;65(1):78-80</RefSource>
                <PMID Version="1">3940472</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Thorac Cardiovasc Surg. 1986 Jun;91(6):858-66</RefSource>
                <PMID Version="1">3520158</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Anesth Analg. 1987 Mar;66(3):249-61</RefSource>
                <PMID Version="1">3548486</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Anesthesiology. 1987 May;66(5):597-604</RefSource>
                <PMID Version="1">3495208</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 1989 Apr 6;320(14):886-92</RefSource>
                <PMID Version="1">2648147</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Anaesthesist. 1989 Oct;38(10):519-24</RefSource>
                <PMID Version="1">2686485</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Anesthesiology. 1990 Sep;73(3):373-5</RefSource>
                <PMID Version="1">2393123</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Anesthesiology. 1991 Dec;75(6):990-9</RefSource>
                <PMID Version="1">1741521</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Circulation. 1992 Jul;86(1):289-94</RefSource>
                <PMID Version="1">1617779</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Anesth Analg. 1993 Jun;76(6):1213-21</RefSource>
                <PMID Version="1">8498656</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Cardiothorac Vasc Anesth. 1994 Aug;8(4):455-62</RefSource>
                <PMID Version="1">7948806</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 1981 Feb 26;304(9):497-503</RefSource>
                <PMID Version="1">7453783</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001026">Coronary Artery Bypass</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006350">Heart Valve Prosthesis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006494">Heparin Antagonists</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006976">Hypertension, Pulmonary</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007650">Ketanserin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008944">Mitral Valve Insufficiency</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000601">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011479">Protamines</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012702">Serotonin Antagonists</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">PMC325377</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1996</Year>
                <Month>1</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1996</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1996</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8969033</ArticleId>
            <ArticleId IdType="pmc">PMC325377</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">18692088</PMID>
        <DateCreated>
            <Year>2008</Year>
            <Month>10</Month>
            <Day>30</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>01</Month>
            <Day>06</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>09</Month>
            <Day>03</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">0091-3057</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>91</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2008</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Pharmacology, biochemistry, and behavior</Title>
                <ISOAbbreviation>Pharmacol. Biochem. Behav.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Demand for cocaine and food over time.</ArticleTitle>
            <Pagination>
                <MedlinePgn>209-16</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pbb.2008.07.009</ELocationID>
            <Abstract>
                <AbstractText>When reinterpreted, data from Ahmed and Koob [Ahmed, S.H., Koob, G.F., Transition from moderate to excessive drug intake: Change in hedonic set point. Science 1998; 282:298-301.] show that the reinforcing strength of cocaine, an inessential good, increases with experience. However, no such effect obtains with a homeostatically regulated good such as food. The present study evaluated whether this difference could serve to distinguish abused drugs from biologically necessary goods. In Experiment 1, five rats from Christensen, Silberberg, Hursh, Huntsberry and Riley [Christensen, C.J., Silberberg, A., Hursh, S.R., Huntsberry, M.E., Riley, A.L., Essential value of cocaine and food in rats: tests of the exponential model of demand. Psychopharmacology 2008;198(2):221-229.] earned cocaine under a Fixed-Ratio 3 schedule for 7 sessions. Thereafter, in a demand procedure identical to that in Christensen et al., demand was re-assessed by measuring consumption at Fixed Ratios between 3 and 560. In Experiment 2, five different rats from Christensen et al. had their food demand curves re-determined using an identical procedure as the first. When fit with the exponential model, the second determination of cocaine demand in Experiment 1 showed greater essential value than the first, indicating that strength increased with cocaine exposure. In Experiment 2, the re-determined food demand curves showed no change from their initial determination. These results show that the strength of cocaine, but not food, increases with increased experience. Measures of time-based changes in essential value may serve as a basis for distinguishing addictive from non-addictive reinforcers.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Christensen</LastName>
                    <ForeName>Chesley J</ForeName>
                    <Initials>CJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>American University, 4400 Massachusetts Ave, NW, Washington, DC 20016, USA. cc4038a@american.edu</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Silberberg</LastName>
                    <ForeName>Alan</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hursh</LastName>
                    <ForeName>Steven R</ForeName>
                    <Initials>SR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Roma</LastName>
                    <ForeName>Peter G</ForeName>
                    <Initials>PG</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Riley</LastName>
                    <ForeName>Anthony L</ForeName>
                    <Initials>AL</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>F31 DA024493-01</GrantID>
                    <Acronym>DA</Acronym>
                    <Agency>NIDA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2008</Year>
                <Month>07</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Pharmacol Biochem Behav</MedlineTA>
            <NlmUniqueID>0367050</NlmUniqueID>
            <ISSNLinking>0091-3057</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Psychopharmacology (Berl). 1991;105(2):169-74</RefSource>
                <PMID Version="1">1796123</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Psychol Rev. 2008 Jan;115(1):186-98</RefSource>
                <PMID Version="1">18211190</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Psychopharmacology (Berl). 2002 Oct;163(3-4):292-301</RefSource>
                <PMID Version="1">12373430</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Exp Anal Behav. 2003 Jan;79(1):111-35</RefSource>
                <PMID Version="1">12696744</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Psychopharmacology (Berl). 2003 May;167(3):324-32</RefSource>
                <PMID Version="1">12652348</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neuroreport. 2003 Dec 2;14(17):2229-32</RefSource>
                <PMID Version="1">14625453</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 2004 Aug 13;305(5686):1014-7</RefSource>
                <PMID Version="1">15310906</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 2004 Aug 13;305(5686):1017-9</RefSource>
                <PMID Version="1">15310907</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Exp Anal Behav. 1968 May;11(3):Suppl:327-83</RefSource>
                <PMID Version="1">5672248</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Psychopharmacology (Berl). 2008 Jun;198(2):221-9</RefSource>
                <PMID Version="1">18351323</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neuropsychopharmacology. 2008 Aug;33(9):2272-82</RefSource>
                <PMID Version="1">17971831</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Psychopharmacology (Berl). 1992;108(3):295-300</RefSource>
                <PMID Version="1">1523280</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pharmacol Exp Ther. 1973 Jul;186(1):18-30</RefSource>
                <PMID Version="1">4198773</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 1978 Aug 11;201(4355):534-5</RefSource>
                <PMID Version="1">96531</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Drug Alcohol Depend. 1981 Aug;8(1):69-78</RefSource>
                <PMID Version="1">7297414</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Exp Anal Behav. 1991 Sep;56(2):261-75</RefSource>
                <PMID Version="1">1955816</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Exp Anal Behav. 1995 Nov;64(3):373-84</RefSource>
                <PMID Version="1">8551194</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Psychopharmacology (Berl). 1996 Jun;125(3):202-8</RefSource>
                <PMID Version="1">8815954</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Drug Alcohol Depend. 1997 Dec;49(1):71-8</RefSource>
                <PMID Version="1">9476702</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 1998 Oct 9;282(5387):298-300</RefSource>
                <PMID Version="1">9765157</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Psychopharmacology (Berl). 1999 Jan;141(1):47-56</RefSource>
                <PMID Version="1">9952064</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Exp Anal Behav. 1999 Sep;72(2):215-34</RefSource>
                <PMID Version="1">10503299</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Exp Anal Behav. 1963 Jul;6:387-92</RefSource>
                <PMID Version="1">13963807</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pharmacol Exp Ther. 2005 Jan;312(1):96-102</RefSource>
                <PMID Version="1">15340005</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Psychopharmacology (Berl). 2005 May;179(3):644-51</RefSource>
                <PMID Version="1">15650844</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Psychopharmacology (Berl). 2005 Jul;180(3):473-90</RefSource>
                <PMID Version="1">15731896</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Psychopharmacology (Berl). 2006 May;186(1):99-106</RefSource>
                <PMID Version="1">16568283</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Psychopharmacology (Berl). 2006 Jun;186(2):168-76</RefSource>
                <PMID Version="1">16596400</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS One. 2007;2(8):e698</RefSource>
                <PMID Version="1">17668074</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Psychopharmacology (Berl). 2008 Jan;195(4):517-25</RefSource>
                <PMID Version="1">17879088</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Addict. 2000 Fall;9(4):285-313</RefSource>
                <PMID Version="1">11155784</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019970">Cocaine-Related Disorders</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003216">Conditioning, Operant</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004435">Eating</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020318">Rats, Long-Evans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012054">Reinforcement (Psychology)</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012055">Reinforcement Schedule</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">NIHMS78822</OtherID>
        <OtherID Source="NLM">PMC2600519</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2008</Year>
                <Month>5</Month>
                <Day>8</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2008</Year>
                <Month>7</Month>
                <Day>9</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2008</Year>
                <Month>7</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2008</Year>
                <Month>7</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2008</Year>
                <Month>8</Month>
                <Day>12</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>1</Month>
                <Day>7</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2008</Year>
                <Month>8</Month>
                <Day>12</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0091-3057(08)00264-5</ArticleId>
            <ArticleId IdType="doi">10.1016/j.pbb.2008.07.009</ArticleId>
            <ArticleId IdType="pubmed">18692088</ArticleId>
            <ArticleId IdType="pmc">PMC2600519</ArticleId>
            <ArticleId IdType="mid">NIHMS78822</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">18491991</PMID>
        <DateCreated>
            <Year>2008</Year>
            <Month>05</Month>
            <Day>21</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2008</Year>
            <Month>09</Month>
            <Day>18</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2008</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1744-7658</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>17</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2008</Year>
                        <Month>Jun</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Expert opinion on investigational drugs</Title>
                <ISOAbbreviation>Expert Opin Investig Drugs</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The role of urokinase in idiopathic pulmonary fibrosis and implication for therapy.</ArticleTitle>
            <Pagination>
                <MedlinePgn>905-16</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1517/13543784.17.6.905</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and frequently fatal form of interstitial lung disease for which there are no proven drug therapies. The pathogenesis of IPF is complex and the urokinase-type plasminogen activator (uPA)/plasminogen system participates in the repair process. The balance between the activating enzyme uPA, and its inhibitor PAI-1, is a critical determinant of the amount of scar development that follows.</AbstractText>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To address the role of urokinase in the pathogenesis of pulmonary fibrosis and its implications for therapy.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">We reviewed a spectrum of therapeutic strategies and focused on fibrinolytic and anticoagulant drugs for IPF patients.</AbstractText>
                <AbstractText Label="RESULTS/CONCLUSION" NlmCategory="CONCLUSIONS">There is currently a search for new pharmacotherapeutic agents that may modulate the fibrogenic pathways in IPF. Either blocking PAI-1 or using uPA itself may be a promising new therapeutic strategy.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Gharaee-Kermani</LastName>
                    <ForeName>Mehrnaz</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Michigan Medical School, Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, 2215 Fuller Road, 11R, Ann Arbor, MI 48105, USA. nazy@umich.edu</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hu</LastName>
                    <ForeName>Biao</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Phan</LastName>
                    <ForeName>Sem H</ForeName>
                    <Initials>SH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gyetko</LastName>
                    <ForeName>Margaret R</ForeName>
                    <Initials>MR</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>HL28737</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>HL31963</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>HL52285</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Expert Opin Investig Drugs</MedlineTA>
            <NlmUniqueID>9434197</NlmUniqueID>
            <ISSNLinking>1354-3784</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D005343">Fibrinolytic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C524898">PLAUR protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017395">Plasminogen Activator Inhibitor 1</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C524899">Plaur protein, mouse</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C524900">Plaur protein, rat</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011956">Receptors, Cell Surface</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D055293">Receptors, Urokinase Plasminogen Activator</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C051321">SERPINE1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>11056-06-7</RegistryNumber>
                <NameOfSubstance UI="D001761">Bleomycin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9001-91-6</RegistryNumber>
                <NameOfSubstance UI="D010958">Plasminogen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9007-34-5</RegistryNumber>
                <NameOfSubstance UI="D003094">Collagen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.4.21.73</RegistryNumber>
                <NameOfSubstance UI="D014568">Urokinase-Type Plasminogen Activator</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000347">Afibrinogenemia</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000925">Anticoagulants</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001761">Bleomycin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002921">Cicatrix</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000517">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003094">Collagen</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015195">Drug Design</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004353">Drug Evaluation, Preclinical</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004789">Enzyme Activation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005343">Fibrinolytic Agents</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010958">Plasminogen</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017395">Plasminogen Activator Inhibitor 1</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011658">Pulmonary Fibrosis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011817">Rabbits</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011956">Receptors, Cell Surface</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D055293">Receptors, Urokinase Plasminogen Activator</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014568">Urokinase-Type Plasminogen Activator</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <NumberOfReferences>98</NumberOfReferences>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2008</Year>
                <Month>5</Month>
                <Day>22</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2008</Year>
                <Month>9</Month>
                <Day>19</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2008</Year>
                <Month>5</Month>
                <Day>22</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1517/13543784.17.6.905</ArticleId>
            <ArticleId IdType="pubmed">18491991</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">24097066</PMID>
        <DateCreated>
            <Year>2013</Year>
            <Month>10</Month>
            <Day>29</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>01</Month>
            <Day>08</Day>
        </DateCompleted>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1546-1718</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>45</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Nature genetics</Title>
                <ISOAbbreviation>Nat. Genet.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>A genome-wide association study in Han Chinese identifies a susceptibility locus for primary Sjögren's syndrome at 7q11.23.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1361-5</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/ng.2779</ELocationID>
            <Abstract>
                <AbstractText>Primary Sjögren's syndrome is one of the most common autoimmune diseases. So far, genetic studies of Sjögren's syndrome have relied mostly on candidate gene approaches. To identify new genetic susceptibility loci for primary Sjögren's syndrome, we performed a three-stage genome-wide association study in Han Chinese. In the discovery stage, we analyzed 556,134 autosomal SNPs in 542 cases and 1,050 controls. We then validated promising associations in 2 replication stages comprising 1,303 cases and 2,727 controls. The combined analysis identified GTF2I at 7q11.23 (rs117026326: Pcombined = 1.31 × 10(-53), combined odds ratio (ORcombined) = 2.20) as a new susceptibility locus for primary Sjögren's syndrome. Our analysis also confirmed previously reported associations in Europeans in the regions of STAT4, TNFAIP3 and the major histocompatibility complex (MHC). Fine mapping of the region around GTF2I showed that rs117026326 in GTF2I had the most significant association, with associated SNPs extending from GTF2I to GTF2IRD1-GTF2I.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Yongzhe</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China. [2].</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Kunlin</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Hua</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sun</LastName>
                    <ForeName>Fei</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xu</LastName>
                    <ForeName>Juanjuan</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Ziyan</ForeName>
                    <Initials>Z</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Ping</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Liuyan</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Du</LastName>
                    <ForeName>Yang</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Luan</LastName>
                    <ForeName>Haixia</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Xi</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Lijun</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Hongbin</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Huaxiang</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Xiangpei</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Xiaomei</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Xiao</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gong</LastName>
                    <ForeName>Lu</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dai</LastName>
                    <ForeName>Lie</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sun</LastName>
                    <ForeName>Lingyun</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zuo</LastName>
                    <ForeName>Xiaoxia</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xu</LastName>
                    <ForeName>Jianhua</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gong</LastName>
                    <ForeName>Huiping</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Zhijun</ForeName>
                    <Initials>Z</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tong</LastName>
                    <ForeName>Shengquan</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Min</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Xiaofeng</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xiao</LastName>
                    <ForeName>Weiguo</ForeName>
                    <Initials>W</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Guochun</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhu</LastName>
                    <ForeName>Ping</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shen</LastName>
                    <ForeName>Min</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Shengyun</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhao</LastName>
                    <ForeName>Dongbao</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Wei</ForeName>
                    <Initials>W</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Yi</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Huang</LastName>
                    <ForeName>Cibo</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jiang</LastName>
                    <ForeName>Quan</ForeName>
                    <Initials>Q</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Guijian</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Bin</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hu</LastName>
                    <ForeName>Shaoxian</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Wen</ForeName>
                    <Initials>W</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Zhuoli</ForeName>
                    <Initials>Z</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>You</LastName>
                    <ForeName>Xin</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Mengtao</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hao</LastName>
                    <ForeName>Weixin</ForeName>
                    <Initials>W</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhao</LastName>
                    <ForeName>Cheng</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Leng</LastName>
                    <ForeName>Xiaomei</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bi</LastName>
                    <ForeName>Liqi</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Yongfu</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Fengxiao</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shi</LastName>
                    <ForeName>Qun</ForeName>
                    <Initials>Q</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Qi</LastName>
                    <ForeName>Wencheng</ForeName>
                    <Initials>W</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Xuewu</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jia</LastName>
                    <ForeName>Yuan</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Su</LastName>
                    <ForeName>Jinmei</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Qin</ForeName>
                    <Initials>Q</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hou</LastName>
                    <ForeName>Yong</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Qingjun</ForeName>
                    <Initials>Q</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xu</LastName>
                    <ForeName>Dong</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zheng</LastName>
                    <ForeName>Wenjie</ForeName>
                    <Initials>W</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Miaojia</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Qian</ForeName>
                    <Initials>Q</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fei</LastName>
                    <ForeName>Yunyun</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Xuan</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Jing</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jiang</LastName>
                    <ForeName>Ying</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tian</LastName>
                    <ForeName>Xinping</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhao</LastName>
                    <ForeName>Lidan</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Li</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhou</LastName>
                    <ForeName>Bin</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Yang</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhao</LastName>
                    <ForeName>Yan</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zeng</LastName>
                    <ForeName>Xiaofeng</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ott</LastName>
                    <ForeName>Jurg</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Jing</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Fengchun</ForeName>
                    <Initials>F</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2013</Year>
                <Month>10</Month>
                <Day>06</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Nat Genet</MedlineTA>
            <NlmUniqueID>9216904</NlmUniqueID>
            <ISSNLinking>1061-4036</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C104259">GTF2I protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D050797">STAT4 Transcription Factor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C494090">STAT4 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D019473">Transcription Factors, TFII</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 6.3.2.19</RegistryNumber>
                <NameOfSubstance UI="C076529">TNFAIP3 protein, human</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" Type="Geographic" UI="D002681">China</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002897">Chromosomes, Human, Pair 7</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004268">DNA-Binding Proteins</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020022">Genetic Predisposition to Disease</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D055106">Genome-Wide Association Study</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D047908">Intracellular Signaling Peptides and Proteins</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008285">Major Histocompatibility Complex</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009687">Nuclear Proteins</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020641">Polymorphism, Single Nucleotide</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D050797">STAT4 Transcription Factor</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012859">Sjogren's Syndrome</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019473">Transcription Factors, TFII</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>6</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2013</Year>
                <Month>9</Month>
                <Day>06</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2013</Year>
                <Month>10</Month>
                <Day>06</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>10</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>10</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>1</Month>
                <Day>9</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ng.2779</ArticleId>
            <ArticleId IdType="doi">10.1038/ng.2779</ArticleId>
            <ArticleId IdType="pubmed">24097066</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">24097067</PMID>
        <DateCreated>
            <Year>2013</Year>
            <Month>10</Month>
            <Day>29</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>01</Month>
            <Day>08</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2015</Year>
            <Month>04</Month>
            <Day>03</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1546-1718</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>45</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Nature genetics</Title>
                <ISOAbbreviation>Nat. Genet.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjögren's syndrome.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1284-92</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/ng.2792</ELocationID>
            <Abstract>
                <AbstractText>Sjögren's syndrome is a common autoimmune disease (affecting ∼0.7% of European Americans) that typically presents as keratoconjunctivitis sicca and xerostomia. Here we report results of a large-scale association study of Sjögren's syndrome. In addition to strong association within the human leukocyte antigen (HLA) region at 6p21 (Pmeta = 7.65 × 10(-114)), we establish associations with IRF5-TNPO3 (Pmeta = 2.73 × 10(-19)), STAT4 (Pmeta = 6.80 × 10(-15)), IL12A (Pmeta = 1.17 × 10(-10)), FAM167A-BLK (Pmeta = 4.97 × 10(-10)), DDX6-CXCR5 (Pmeta = 1.10 × 10(-8)) and TNIP1 (Pmeta = 3.30 × 10(-8)). We also observed suggestive associations (Pmeta &lt; 5 × 10(-5)) with variants in 29 other regions, including TNFAIP3, PTTG1, PRDM1, DGKQ, FCGR2A, IRAK1BP1, ITSN2 and PHIP, among others. These results highlight the importance of genes that are involved in both innate and adaptive immunity in Sjögren's syndrome.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Lessard</LastName>
                    <ForeName>Christopher J</ForeName>
                    <Initials>CJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA. [2] Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>He</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Adrianto</LastName>
                    <ForeName>Indra</ForeName>
                    <Initials>I</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ice</LastName>
                    <ForeName>John A</ForeName>
                    <Initials>JA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rasmussen</LastName>
                    <ForeName>Astrid</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Grundahl</LastName>
                    <ForeName>Kiely M</ForeName>
                    <Initials>KM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kelly</LastName>
                    <ForeName>Jennifer A</ForeName>
                    <Initials>JA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dozmorov</LastName>
                    <ForeName>Mikhail G</ForeName>
                    <Initials>MG</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Miceli-Richard</LastName>
                    <ForeName>Corinne</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bowman</LastName>
                    <ForeName>Simon</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lester</LastName>
                    <ForeName>Sue</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Eriksson</LastName>
                    <ForeName>Per</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Eloranta</LastName>
                    <ForeName>Maija-Leena</ForeName>
                    <Initials>ML</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brun</LastName>
                    <ForeName>Johan G</ForeName>
                    <Initials>JG</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gøransson</LastName>
                    <ForeName>Lasse G</ForeName>
                    <Initials>LG</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Harboe</LastName>
                    <ForeName>Erna</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Guthridge</LastName>
                    <ForeName>Joel M</ForeName>
                    <Initials>JM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kaufman</LastName>
                    <ForeName>Kenneth M</ForeName>
                    <Initials>KM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kvarnström</LastName>
                    <ForeName>Marika</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jazebi</LastName>
                    <ForeName>Helmi</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cunninghame Graham</LastName>
                    <ForeName>Deborah S</ForeName>
                    <Initials>DS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Grandits</LastName>
                    <ForeName>Martha E</ForeName>
                    <Initials>ME</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nazmul-Hossain</LastName>
                    <ForeName>Abu N M</ForeName>
                    <Initials>AN</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Patel</LastName>
                    <ForeName>Ketan</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Adler</LastName>
                    <ForeName>Adam J</ForeName>
                    <Initials>AJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Maier-Moore</LastName>
                    <ForeName>Jacen S</ForeName>
                    <Initials>JS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Farris</LastName>
                    <ForeName>A Darise</ForeName>
                    <Initials>AD</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brennan</LastName>
                    <ForeName>Michael T</ForeName>
                    <Initials>MT</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lessard</LastName>
                    <ForeName>James A</ForeName>
                    <Initials>JA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chodosh</LastName>
                    <ForeName>James</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gopalakrishnan</LastName>
                    <ForeName>Rajaram</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hefner</LastName>
                    <ForeName>Kimberly S</ForeName>
                    <Initials>KS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Houston</LastName>
                    <ForeName>Glen D</ForeName>
                    <Initials>GD</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Huang</LastName>
                    <ForeName>Andrew J W</ForeName>
                    <Initials>AJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hughes</LastName>
                    <ForeName>Pamela J</ForeName>
                    <Initials>PJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lewis</LastName>
                    <ForeName>David M</ForeName>
                    <Initials>DM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Radfar</LastName>
                    <ForeName>Lida</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rohrer</LastName>
                    <ForeName>Michael D</ForeName>
                    <Initials>MD</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stone</LastName>
                    <ForeName>Donald U</ForeName>
                    <Initials>DU</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wren</LastName>
                    <ForeName>Jonathan D</ForeName>
                    <Initials>JD</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vyse</LastName>
                    <ForeName>Timothy J</ForeName>
                    <Initials>TJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gaffney</LastName>
                    <ForeName>Patrick M</ForeName>
                    <Initials>PM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>James</LastName>
                    <ForeName>Judith A</ForeName>
                    <Initials>JA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Omdal</LastName>
                    <ForeName>Roald</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wahren-Herlenius</LastName>
                    <ForeName>Marie</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Illei</LastName>
                    <ForeName>Gabor G</ForeName>
                    <Initials>GG</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Witte</LastName>
                    <ForeName>Torsten</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jonsson</LastName>
                    <ForeName>Roland</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rischmueller</LastName>
                    <ForeName>Maureen</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rönnblom</LastName>
                    <ForeName>Lars</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nordmark</LastName>
                    <ForeName>Gunnel</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ng</LastName>
                    <ForeName>Wan-Fai</ForeName>
                    <Initials>WF</Initials>
                </Author>
                <Author ValidYN="Y">
                    <CollectiveName>UK Primary Sjögren's Syndrome Registry</CollectiveName>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mariette</LastName>
                    <ForeName>Xavier</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Anaya</LastName>
                    <ForeName>Juan-Manuel</ForeName>
                    <Initials>JM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rhodus</LastName>
                    <ForeName>Nelson L</ForeName>
                    <Initials>NL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Segal</LastName>
                    <ForeName>Barbara M</ForeName>
                    <Initials>BM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Scofield</LastName>
                    <ForeName>R Hal</ForeName>
                    <Initials>RH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Montgomery</LastName>
                    <ForeName>Courtney G</ForeName>
                    <Initials>CG</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Harley</LastName>
                    <ForeName>John B</ForeName>
                    <Initials>JB</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sivils</LastName>
                    <ForeName>Kathy L</ForeName>
                    <Initials>KL</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>1R01 DE018209-02</GrantID>
                    <Acronym>DE</Acronym>
                    <Agency>NIDCR NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>1RC1 AR058554</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>1U01 AI101934</GrantID>
                    <Acronym>AI</Acronym>
                    <Agency>NIAID NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>5P01 AI083194-03</GrantID>
                    <Acronym>AI</Acronym>
                    <Agency>NIAID NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>5P01 AR049084-10</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>5P30 AR053483</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>5P30 GM103510</GrantID>
                    <Acronym>GM</Acronym>
                    <Agency>NIGMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>5R01 DE015223</GrantID>
                    <Acronym>DE</Acronym>
                    <Agency>NIDCR NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>5R01 DE018209</GrantID>
                    <Acronym>DE</Acronym>
                    <Agency>NIDCR NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>5R37 AI024717-25</GrantID>
                    <Acronym>AI</Acronym>
                    <Agency>NIAID NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>5RC2 AR058959</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>5U19 AI082714</GrantID>
                    <Acronym>AI</Acronym>
                    <Agency>NIAID NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>7S10 RR027190-02</GrantID>
                    <Acronym>RR</Acronym>
                    <Agency>NCRR NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>8P20 GM103456</GrantID>
                    <Acronym>GM</Acronym>
                    <Agency>NIGMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>G0800629</GrantID>
                    <Agency>Medical Research Council</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>MR/J002720/1</GrantID>
                    <Agency>Medical Research Council</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>P01 AI083194</GrantID>
                    <Acronym>AI</Acronym>
                    <Agency>NIAID NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P20 GM103456</GrantID>
                    <Acronym>GM</Acronym>
                    <Agency>NIGMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P20 GM103636</GrantID>
                    <Acronym>GM</Acronym>
                    <Agency>NIGMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P20 GM103636</GrantID>
                    <Acronym>GM</Acronym>
                    <Agency>NIGMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P30 AR053483</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P30 GM103510</GrantID>
                    <Acronym>GM</Acronym>
                    <Agency>NIGMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P50 AR060804</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P50 AR0608040</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 DE015223</GrantID>
                    <Acronym>DE</Acronym>
                    <Agency>NIDCR NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 DE018209</GrantID>
                    <Acronym>DE</Acronym>
                    <Agency>NIDCR NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R37 AI024717</GrantID>
                    <Acronym>AI</Acronym>
                    <Agency>NIAID NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>RC1 AR058554</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U01 AI101934</GrantID>
                    <Acronym>AI</Acronym>
                    <Agency>NIAID NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U19 AI082714</GrantID>
                    <Acronym>AI</Acronym>
                    <Agency>NIAID NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>UK G0800629</GrantID>
                    <Agency>Medical Research Council</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
                <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2013</Year>
                <Month>10</Month>
                <Day>06</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Nat Genet</MedlineTA>
            <NlmUniqueID>9216904</NlmUniqueID>
            <ISSNLinking>1061-4036</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000949">Histocompatibility Antigens Class II</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Autoimmun. 2009 Sep;33(2):99-108</RefSource>
                <PMID Version="1">19523788</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2009 Nov;41(11):1228-33</RefSource>
                <PMID Version="1">19838195</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Immunol Cell Biol. 2009 Nov-Dec;87(8):590-600</RefSource>
                <PMID Version="1">19721453</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Immunol Immunother. 2010 Apr;59(4):489-510</RefSource>
                <PMID Version="1">20049431</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nucleic Acids Res. 2010 Jan;38(3):e17</RefSource>
                <PMID Version="1">19923232</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bioinformatics. 2010 Mar 15;26(6):841-2</RefSource>
                <PMID Version="1">20110278</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2010 May;42(5):426-9</RefSource>
                <PMID Version="1">20383147</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2010 Jun;42(6):508-14</RefSource>
                <PMID Version="1">20453842</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genes Immun. 2010 Jul;11(5):432-8</RefSource>
                <PMID Version="1">20535138</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2010 Aug;42(8):658-60</RefSource>
                <PMID Version="1">20639880</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bioinformatics. 2010 Sep 1;26(17):2190-1</RefSource>
                <PMID Version="1">20616382</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bioinformatics. 2010 Sep 15;26(18):2336-7</RefSource>
                <PMID Version="1">20634204</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Dev Immunol. 2010;2010. pii: 832454. doi: 10.1155/2010/832454</RefSource>
                <PMID Version="1">20885915</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Rheum Dis. 2011 Jan;70(1):117-21</RefSource>
                <PMID Version="1">20980283</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nucleic Acids Res. 2011 Jan;39(Database issue):D876-82</RefSource>
                <PMID Version="1">20959295</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS Genet. 2011;7(1):e1001273</RefSource>
                <PMID Version="1">21249183</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2011 Mar;43(3):253-8</RefSource>
                <PMID Version="1">21336280</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genes Immun. 2011 Mar;12(2):100-9</RefSource>
                <PMID Version="1">20861858</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2011 Apr;43(4):329-32</RefSource>
                <PMID Version="1">21399635</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS Biol. 2011 Apr;9(4):e1001046</RefSource>
                <PMID Version="1">21526222</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Rheumatol. 2011 May;38(5):797-801</RefSource>
                <PMID Version="1">21362769</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS Genet. 2011 Jul;7(7):e1002091</RefSource>
                <PMID Version="1">21750679</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2011 Aug 11;476(7359):214-9</RefSource>
                <PMID Version="1">21833088</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arthritis Res Ther. 2011;13(1):101</RefSource>
                <PMID Version="1">21345260</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Immunol Lett. 2011 Dec 30;141(1):1-9</RefSource>
                <PMID Version="1">21777618</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bioinformatics. 2012 Feb 1;28(3):419-20</RefSource>
                <PMID Version="1">22155868</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Autoimmun Rev. 2012 Feb;11(4):281-7</RefSource>
                <PMID Version="1">22001416</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2012 Mar;44(3):291-6</RefSource>
                <PMID Version="1">22286218</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Hum Genet. 2012 Apr 6;90(4):648-60</RefSource>
                <PMID Version="1">22464253</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Immunol. 2012 May 15;188(10):4951-8</RefSource>
                <PMID Version="1">22490869</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bioinformatics. 2012 May 15;28(10):1353-8</RefSource>
                <PMID Version="1">22492648</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Autoimmun. 2012 Aug;39(1-2):57-63</RefSource>
                <PMID Version="1">22289719</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Mol Genet. 2012 Sep 1;21(17):3918-25</RefSource>
                <PMID Version="1">22678060</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arthritis Rheum. 2012 Nov;64(11):3695-705</RefSource>
                <PMID Version="1">22833143</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenomics J. 2014 Apr;14(2):192-200</RefSource>
                <PMID Version="1">23712092</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Exp Med. 2000 Jun 5;191(11):1813-7</RefSource>
                <PMID Version="1">10839798</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Hum Genet. 2000 Mar;64(Pt 2):171-86</RefSource>
                <PMID Version="1">11246470</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mayo Clin Proc. 2001 Jun;76(6):593-9</RefSource>
                <PMID Version="1">11393497</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Immunol. 2001 Jul;62(7):725-31</RefSource>
                <PMID Version="1">11423179</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Rheum Dis. 2002 Jun;61(6):554-8</RefSource>
                <PMID Version="1">12006334</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Immunol. 2002 Nov;3(11):1075-81</RefSource>
                <PMID Version="1">12368908</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biostatistics. 2003 Apr;4(2):249-64</RefSource>
                <PMID Version="1">12925520</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>BMJ. 2003 Sep 6;327(7414):557-60</RefSource>
                <PMID Version="1">12958120</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Rheum Dis. 2004 Jul;63(7):874-6</RefSource>
                <PMID Version="1">15194588</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Immunol. 1993 Apr 15;150(8 Pt 1):3615-23</RefSource>
                <PMID Version="1">8468491</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Novartis Found Symp. 1998;215:21-30; discussion 30-40</RefSource>
                <PMID Version="1">9760569</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Immunol Rev. 2004 Dec;202:139-56</RefSource>
                <PMID Version="1">15546391</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bioinformatics. 2005 Jan 15;21(2):263-5</RefSource>
                <PMID Version="1">15297300</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Hum Genet. 2005 Mar;76(3):528-37</RefSource>
                <PMID Version="1">15657875</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2005 Mar 10;434(7030):243-9</RefSource>
                <PMID Version="1">15665823</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arthritis Rheum. 2005 May;52(5):1534-44</RefSource>
                <PMID Version="1">15880807</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Immunol Res. 2005;31(3):231-42</RefSource>
                <PMID Version="1">15888914</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2770-5</RefSource>
                <PMID Version="1">16477017</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2006 Aug;38(8):904-9</RefSource>
                <PMID Version="1">16862161</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biostatistics. 2007 Jan;8(1):118-27</RefSource>
                <PMID Version="1">16632515</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2007 Apr 17;104(16):6758-63</RefSource>
                <PMID Version="1">17412832</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arthritis Rheum. 2007 Jul;56(7):2202-10</RefSource>
                <PMID Version="1">17599733</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Hum Genet. 2007 Sep;81(3):559-75</RefSource>
                <PMID Version="1">17701901</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2007 Sep 6;357(10):977-86</RefSource>
                <PMID Version="1">17804842</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2007 Oct 18;449(7164):851-61</RefSource>
                <PMID Version="1">17943122</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Mol Genet. 2007 Dec 15;16(24):3008-16</RefSource>
                <PMID Version="1">17881657</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arthritis Rheum. 2007 Dec;56(12):3989-94</RefSource>
                <PMID Version="1">18050197</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arthritis Res Ther. 2007;9(4):218</RefSource>
                <PMID Version="1">17697366</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arthritis Rheum. 2008 Jan;58(1):15-25</RefSource>
                <PMID Version="1">18163481</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2008 Feb;40(2):204-10</RefSource>
                <PMID Version="1">18204446</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2008 Feb 28;358(9):900-9</RefSource>
                <PMID Version="1">18204098</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Mol Genet. 2008 Mar 15;17(6):872-81</RefSource>
                <PMID Version="1">18063667</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Semin Arthritis Rheum. 2008 Apr;37(5):273-92</RefSource>
                <PMID Version="1">17714766</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2008 Apr;40(4):395-402</RefSource>
                <PMID Version="1">18311140</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Mutat. 2008 May;29(5):648-58</RefSource>
                <PMID Version="1">18286470</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genes Immun. 2008 Apr;9(3):267-70</RefSource>
                <PMID Version="1">18273036</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Med Genet. 2008 Jun;45(6):362-9</RefSource>
                <PMID Version="1">18285424</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Rheum Dis Clin North Am. 2008 Nov;34(4):847-68, vii</RefSource>
                <PMID Version="1">18984408</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arthritis Rheum. 2009 Jan;60(1):225-33</RefSource>
                <PMID Version="1">19116937</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genes Immun. 2009 Jan;10(1):68-76</RefSource>
                <PMID Version="1">19092842</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2009 Feb;41(2):199-204</RefSource>
                <PMID Version="1">19169254</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Mol Genet. 2009 Jun 1;18(11):2071-7</RefSource>
                <PMID Version="1">19286670</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genes Immun. 2009 Jun;10(4):285-96</RefSource>
                <PMID Version="1">19404300</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2009 Jun 11;360(24):2544-55</RefSource>
                <PMID Version="1">19458352</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS Genet. 2009 Jun;5(6):e1000529</RefSource>
                <PMID Version="1">19543373</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nucleic Acids Res. 2009 Jul;37(Web Server issue):W135-40</RefSource>
                <PMID Version="1">19417065</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arthritis Rheum. 2009 Jul;60(7):1991-7</RefSource>
                <PMID Version="1">19565491</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D056704">Adaptive Immunity</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D056726">Genetic Association Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D056426">Genetic Loci</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014644">Genetic Variation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000949">Histocompatibility Antigens Class II</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007113">Immunity, Innate</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012859">Sjogren's Syndrome</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">EMS54762</OtherID>
        <OtherID Source="NLM">PMC3867192</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>4</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2013</Year>
                <Month>9</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2013</Year>
                <Month>10</Month>
                <Day>06</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>10</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>10</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>1</Month>
                <Day>9</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ng.2792</ArticleId>
            <ArticleId IdType="doi">10.1038/ng.2792</ArticleId>
            <ArticleId IdType="pubmed">24097067</ArticleId>
            <ArticleId IdType="pmc">PMC3867192</ArticleId>
            <ArticleId IdType="mid">EMS54762</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">3121011</PMID>
        <DateCreated>
            <Year>1988</Year>
            <Month>02</Month>
            <Day>23</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1988</Year>
            <Month>02</Month>
            <Day>23</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0267-0623</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>295</Volume>
                    <Issue>6609</Issue>
                    <PubDate>
                        <Year>1987</Year>
                        <Month>Nov</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>British medical journal (Clinical research ed.)</Title>
                <ISOAbbreviation>Br Med J (Clin Res Ed)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Angiotensin converting enzyme inhibitors and diuretics.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1351-2</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Cook</LastName>
                    <ForeName>B</ForeName>
                    <Initials>B</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016422">Letter</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>ENGLAND</Country>
            <MedlineTA>Br Med J (Clin Res Ed)</MedlineTA>
            <NlmUniqueID>8302911</NlmUniqueID>
            <ISSNLinking>0267-0623</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>75945-58-3</RegistryNumber>
                <NameOfSubstance UI="C041760">furotriam</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>7LXU5N7ZO5</RegistryNumber>
                <NameOfSubstance UI="D005665">Furosemide</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9G64RSX1XD</RegistryNumber>
                <NameOfSubstance UI="D002216">Captopril</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>WS821Z52LQ</RegistryNumber>
                <NameOfSubstance UI="D014223">Triamterene</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Med. 1982 Nov;73(5):719-25</RefSource>
                <PMID Version="1">6291388</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Cardiol. 1986 Feb 1;57(4):347-8</RefSource>
                <PMID Version="1">3004185</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Pharmacol Ther. 1985 Dec;38(6):613-7</RefSource>
                <PMID Version="1">2998675</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002216">Captopril</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004338">Drug Combinations</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005665">Furosemide</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000032">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009120">Muscle Cramp</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014223">Triamterene</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000032">analysis</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">PMC1248422</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1987</Year>
                <Month>11</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1987</Year>
                <Month>11</Month>
                <Day>21</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1987</Year>
                <Month>11</Month>
                <Day>21</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3121011</ArticleId>
            <ArticleId IdType="pmc">PMC1248422</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">2752702</PMID>
        <DateCreated>
            <Year>1989</Year>
            <Month>09</Month>
            <Day>01</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1989</Year>
            <Month>09</Month>
            <Day>01</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0278-2677</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>8</Volume>
                    <Issue>7</Issue>
                    <PubDate>
                        <Year>1989</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical pharmacy</Title>
                <ISOAbbreviation>Clin Pharm</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Phenytoin-induced hepatitis, rhabdomyolysis, and renal dysfunction.</ArticleTitle>
            <Pagination>
                <MedlinePgn>514-5</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Korman</LastName>
                    <ForeName>L B</ForeName>
                    <Initials>LB</Initials>
                    <AffiliationInfo>
                        <Affiliation>College of Pharmacy, Rutgers University, East Orange, NJ.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Olson</LastName>
                    <ForeName>M J</ForeName>
                    <Initials>MJ</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Clin Pharm</MedlineTA>
            <NlmUniqueID>8207437</NlmUniqueID>
            <ISSNLinking>0278-2677</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>6158TKW0C5</RegistryNumber>
                <NameOfSubstance UI="D010672">Phenytoin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D056486">Drug-Induced Liver Injury</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007674">Kidney Diseases</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007677">Kidney Function Tests</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010672">Phenytoin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012206">Rhabdomyolysis</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012640">Seizures</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1989</Year>
                <Month>7</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1989</Year>
                <Month>7</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1989</Year>
                <Month>7</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2752702</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">10694546</PMID>
        <DateCreated>
            <Year>2000</Year>
            <Month>03</Month>
            <Day>24</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2000</Year>
            <Month>03</Month>
            <Day>24</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2007</Year>
            <Month>11</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0732-183X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>18</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2000</Year>
                        <Month>Mar</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</Title>
                <ISOAbbreviation>J. Clin. Oncol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Assessment of the stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group pilot study E1492.</ArticleTitle>
            <Pagination>
                <MedlinePgn>972-80</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">This study was performed, in a multi-institutional setting, to evaluate the efficacy and feasibility of the Stanford V chemotherapy regimen plus radiotherapy to bulky Hodgkin's disease sites.</AbstractText>
                <AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">A two-stage design was implemented in a phase II study involving 47 patients with bulky mediastinal stage I/II or stage III/IV Hodgkin's disease. Twelve weeks of the Stanford V chemotherapy regimen were given with consolidative radiotherapy (36 Gy) to lymph nodes &gt;/= 5 cm and/or macroscopic splenic disease. Treatment was administered in one of five institutions participating in the Eastern Cooperative Oncology Group.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">With a median follow-up of 4.8 years, 45 patients are alive and 40 have been continuously disease-free. The estimated freedom from progression was 87% at 2 years and 85% at 5 years. Overall survival was 96% at 2 and 5 years. There was one death from Hodgkin's disease and one death from an M5 acute leukemia. Six of seven relapsed patients received high-dose therapy and autologous stem-cell transplantation. The freedom from second progression for the seven relapsed patients was estimated at 98% at 3 years.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Stanford V chemotherapy and consolidative radiotherapy to bulky disease is effective in bulky and advanced Hodgkin's disease in a multi-institutional setting. On this basis, an Intergroup study comparing doxorubicin, bleomycin, vinblastine, and dacarbazine with the Stanford V regimen has been initiated.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Horning</LastName>
                    <ForeName>S J</ForeName>
                    <Initials>SJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Stanford University Medical Center, Stanford, CA, USA. ml.xsh@forsythe.stanford.edu</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Williams</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bartlett</LastName>
                    <ForeName>N L</ForeName>
                    <Initials>NL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bennett</LastName>
                    <ForeName>J M</ForeName>
                    <Initials>JM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hoppe</LastName>
                    <ForeName>R T</ForeName>
                    <Initials>RT</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Neuberg</LastName>
                    <ForeName>D</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cassileth</LastName>
                    <ForeName>P</ForeName>
                    <Initials>P</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="N">
                <Grant>
                    <GrantID>CA11083</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>CA23318</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>CA66636</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016430">Clinical Trial</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016448">Multicenter Study</PublicationType>
                <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>J Clin Oncol</MedlineTA>
            <NlmUniqueID>8309333</NlmUniqueID>
            <ISSNLinking>0732-183X</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003131">Combined Modality Therapy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005240">Feasibility Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006689">Hodgkin Disease</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000532">radiotherapy</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009367">Neoplasm Staging</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011786">Quality Control</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016019">Survival Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2000</Year>
                <Month>3</Month>
                <Day>1</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2000</Year>
                <Month>4</Month>
                <Day>1</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2000</Year>
                <Month>3</Month>
                <Day>1</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10694546</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">8068996</PMID>
        <DateCreated>
            <Year>1994</Year>
            <Month>09</Month>
            <Day>23</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1994</Year>
            <Month>09</Month>
            <Day>23</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1060-0280</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>28</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>1994</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The Annals of pharmacotherapy</Title>
                <ISOAbbreviation>Ann Pharmacother</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Treatment of cyclophosphamide-induced hemorrhagic cystitis with prostaglandins.</ArticleTitle>
            <Pagination>
                <MedlinePgn>590-4</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To report a case of cyclophosphamide-induced hemorrhagic cystitis, discuss prevention, and review treatment options, particularly the use of intravesicular prostaglandins.</AbstractText>
                <AbstractText Label="DATA SOURCES" NlmCategory="METHODS">Literature obtained through a computerized search, with subsequent bibliography scanning. Information on the individual case was obtained from the patient's medical record and the Pharmacy Clinical Research Specialist.</AbstractText>
                <AbstractText Label="CASE SUMMARY" NlmCategory="METHODS">A 29-year-old woman who had a postallogeneic bone marrow transplantation was hospitalized because of graft-versus-host disease. During hospitalization, she developed a cyclophosphamide-induced hematuria that, despite hydration and transfusions of blood products, progressed to refractory hemorrhagic cystitis. A response was prompted ultimately by a regimen consisting of continuous bladder irrigation and intermittent intravesical instillation of carboprost.</AbstractText>
                <AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">The best treatment for hemorrhagic cystitis remains prevention. Therapies for established cystitis are varied; the choice depends on the degree of hematuria present. Therapies are often temporary or ineffective, and themselves cause significant morbidity. One promising treatment option involves the intravesicular administration of prostaglandins. Reports in the literature discuss a variety of products, dosages, and treatment schedules that have been used with some success. The available data on this technique are presented.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Prostaglandins appear to be effective in resolving established hemorrhagic cystitis; however, their place in therapy remains unclear. Before this class can be employed routinely, several basic issues remain. These include optimal dosage, dosing schedule, duration of treatment, and comparative efficacy with other agents.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Miller</LastName>
                    <ForeName>L J</ForeName>
                    <Initials>LJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Pharmacy, University of Texas M.D. Anderson Cancer Center, Houston 77030.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chandler</LastName>
                    <ForeName>S W</ForeName>
                    <Initials>SW</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ippoliti</LastName>
                    <ForeName>C M</ForeName>
                    <Initials>CM</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Ann Pharmacother</MedlineTA>
            <NlmUniqueID>9203131</NlmUniqueID>
            <ISSNLinking>1060-0280</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>7B5032XT6O</RegistryNumber>
                <NameOfSubstance UI="D002260">Carboprost</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>8N3DW7272P</RegistryNumber>
                <NameOfSubstance UI="D003520">Cyclophosphamide</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000283">Administration, Intravesical</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016026">Bone Marrow Transplantation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002260">Carboprost</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003520">Cyclophosphamide</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003556">Cystitis</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006417">Hematuria</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006470">Hemorrhage</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007507">Therapeutic Irrigation</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <NumberOfReferences>28</NumberOfReferences>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1994</Year>
                <Month>5</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1994</Year>
                <Month>5</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1994</Year>
                <Month>5</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8068996</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">16236144</PMID>
        <DateCreated>
            <Year>2005</Year>
            <Month>10</Month>
            <Day>20</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2005</Year>
            <Month>12</Month>
            <Day>07</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1742-7835</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>97</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2005</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Basic &amp; clinical pharmacology &amp; toxicology</Title>
                <ISOAbbreviation>Basic Clin. Pharmacol. Toxicol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Activity of d,l-alpha-tocopherol (vitamin E) against cardiotoxicity induced by doxorubicin and doxorubicin with cyclophosphamide in mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>311-9</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>The aim of this study was to investigate the cardioprotective activity of vitamin E against doxorubicin alone and doxorubicin in combination with cyclophosphamide in mice. Female BalbC/NIH mice were treated with vitamin E (100 IU/kg, orally) 24 hr before single bolus doses of doxorubicin (10 mg/kg, intravenously), or doxorubicin and cyclophosphamide (150 mg/kg, intraperitoneally). Non-treated animals served as negative controls, while positive control groups received doxorubicin or doxorubicin and cyclophosphamide. For evaluation, serum enzyme activity of aspartate aminotransferase (AST), lactate dehidrogenase (LDH), alpha-hydroxybutirate dehydrogenase (alpha-HBDH), and creatine kinase (CK) at 48 hr and histopathology examination of the heart tissue (Billigham rules) at 1.5 and 3 months followed to treatments were used. In sera of mice treated with vitamin E prior to doxorubicin, the creatine kinase and % alpha-HBDH activity were significantly reduced, compared to positive control. Histopathology changes (scored as 1.5 at 1.5 and 3 months respectively) were not significant compared to negative control at both time points of examination. In animals which received vitamin E before doxorubicin and cyclophosphamide, none of the serum enzymes was significantly reduced compared to positive control, but non-significant increase in AST and creatine kinase activity was detected (3% and 16.57% respectively). The degree of myocardial damage was significantly higher compared to non-treated group (2.0 and 2.5 at 1.5 and 3 months respectively). Current results show that vitamin E in single oral dose failed to inhibit acute cardiotoxic activity of doxorubicin, but suspended further progression of the heart muscle damage over the time. On the contrary, vitamin E did not attain any cardioprotection against doxorubicin and cyclophosphamide in combination.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Bjelogrlic</LastName>
                    <ForeName>Snezana K</ForeName>
                    <Initials>SK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Experimental Oncology, National Cancer Research Center, Belgrade, Serbia &amp; Montenegro. zanab@bitsyu.net</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Radic</LastName>
                    <ForeName>Jelena</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jovic</LastName>
                    <ForeName>Viktor</ForeName>
                    <Initials>V</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Radulovic</LastName>
                    <ForeName>Sinisa</ForeName>
                    <Initials>S</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Denmark</Country>
            <MedlineTA>Basic Clin Pharmacol Toxicol</MedlineTA>
            <NlmUniqueID>101208422</NlmUniqueID>
            <ISSNLinking>1742-7835</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004798">Enzymes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>1406-18-4</RegistryNumber>
                <NameOfSubstance UI="D014810">Vitamin E</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>80168379AG</RegistryNumber>
                <NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>8N3DW7272P</RegistryNumber>
                <NameOfSubstance UI="D003520">Cyclophosphamide</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000975">Antioxidants</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003520">Cyclophosphamide</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004317">Doxorubicin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004798">Enzymes</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006331">Heart Diseases</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008807">Mice, Inbred BALB C</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009206">Myocardium</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014810">Vitamin E</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2005</Year>
                <Month>10</Month>
                <Day>21</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2005</Year>
                <Month>12</Month>
                <Day>13</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2005</Year>
                <Month>10</Month>
                <Day>21</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">PTOpto_166</ArticleId>
            <ArticleId IdType="doi">10.1111/j.1742-7843.2005.pto_166.x</ArticleId>
            <ArticleId IdType="pubmed">16236144</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">24097064</PMID>
        <DateCreated>
            <Year>2013</Year>
            <Month>10</Month>
            <Day>29</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>01</Month>
            <Day>08</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2015</Year>
            <Month>05</Month>
            <Day>18</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1546-1718</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>45</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Nature genetics</Title>
                <ISOAbbreviation>Nat. Genet.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Common variants associated with plasma triglycerides and risk for coronary artery disease.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1345-52</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/ng.2795</ELocationID>
            <Abstract>
                <AbstractText>Triglycerides are transported in plasma by specific triglyceride-rich lipoproteins; in epidemiological studies, increased triglyceride levels correlate with higher risk for coronary artery disease (CAD). However, it is unclear whether this association reflects causal processes. We used 185 common variants recently mapped for plasma lipids (P &lt; 5 × 10(-8) for each) to examine the role of triglycerides in risk for CAD. First, we highlight loci associated with both low-density lipoprotein cholesterol (LDL-C) and triglyceride levels, and we show that the direction and magnitude of the associations with both traits are factors in determining CAD risk. Second, we consider loci with only a strong association with triglycerides and show that these loci are also associated with CAD. Finally, in a model accounting for effects on LDL-C and/or high-density lipoprotein cholesterol (HDL-C) levels, the strength of a polymorphism's effect on triglyceride levels is correlated with the magnitude of its effect on CAD risk. These results suggest that triglyceride-rich lipoproteins causally influence risk for CAD.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Do</LastName>
                    <ForeName>Ron</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Cardiovascular Research Center, Massachusetts General Hospital, Boston, Massachusetts, USA. [2] Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts, USA. [3] Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA. [4] Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Willer</LastName>
                    <ForeName>Cristen J</ForeName>
                    <Initials>CJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schmidt</LastName>
                    <ForeName>Ellen M</ForeName>
                    <Initials>EM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sengupta</LastName>
                    <ForeName>Sebanti</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gao</LastName>
                    <ForeName>Chi</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Peloso</LastName>
                    <ForeName>Gina M</ForeName>
                    <Initials>GM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gustafsson</LastName>
                    <ForeName>Stefan</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kanoni</LastName>
                    <ForeName>Stavroula</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ganna</LastName>
                    <ForeName>Andrea</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Jin</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Buchkovich</LastName>
                    <ForeName>Martin L</ForeName>
                    <Initials>ML</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mora</LastName>
                    <ForeName>Samia</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Beckmann</LastName>
                    <ForeName>Jacques S</ForeName>
                    <Initials>JS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bragg-Gresham</LastName>
                    <ForeName>Jennifer L</ForeName>
                    <Initials>JL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chang</LastName>
                    <ForeName>Hsing-Yi</ForeName>
                    <Initials>HY</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Demirkan</LastName>
                    <ForeName>Ayşe</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Den Hertog</LastName>
                    <ForeName>Heleen M</ForeName>
                    <Initials>HM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Donnelly</LastName>
                    <ForeName>Louise A</ForeName>
                    <Initials>LA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ehret</LastName>
                    <ForeName>Georg B</ForeName>
                    <Initials>GB</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Esko</LastName>
                    <ForeName>Tõnu</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Feitosa</LastName>
                    <ForeName>Mary F</ForeName>
                    <Initials>MF</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ferreira</LastName>
                    <ForeName>Teresa</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fischer</LastName>
                    <ForeName>Krista</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fontanillas</LastName>
                    <ForeName>Pierre</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fraser</LastName>
                    <ForeName>Ross M</ForeName>
                    <Initials>RM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Freitag</LastName>
                    <ForeName>Daniel F</ForeName>
                    <Initials>DF</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gurdasani</LastName>
                    <ForeName>Deepti</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Heikkilä</LastName>
                    <ForeName>Kauko</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hyppönen</LastName>
                    <ForeName>Elina</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Isaacs</LastName>
                    <ForeName>Aaron</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jackson</LastName>
                    <ForeName>Anne U</ForeName>
                    <Initials>AU</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Johansson</LastName>
                    <ForeName>Asa</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Johnson</LastName>
                    <ForeName>Toby</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kaakinen</LastName>
                    <ForeName>Marika</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kettunen</LastName>
                    <ForeName>Johannes</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kleber</LastName>
                    <ForeName>Marcus E</ForeName>
                    <Initials>ME</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Xiaohui</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Luan</LastName>
                    <ForeName>Jian'an</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lyytikäinen</LastName>
                    <ForeName>Leo-Pekka</ForeName>
                    <Initials>LP</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Magnusson</LastName>
                    <ForeName>Patrik K E</ForeName>
                    <Initials>PK</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mangino</LastName>
                    <ForeName>Massimo</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mihailov</LastName>
                    <ForeName>Evelin</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Montasser</LastName>
                    <ForeName>May E</ForeName>
                    <Initials>ME</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Müller-Nurasyid</LastName>
                    <ForeName>Martina</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nolte</LastName>
                    <ForeName>Ilja M</ForeName>
                    <Initials>IM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>O'Connell</LastName>
                    <ForeName>Jeffrey R</ForeName>
                    <Initials>JR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Palmer</LastName>
                    <ForeName>Cameron D</ForeName>
                    <Initials>CD</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Perola</LastName>
                    <ForeName>Markus</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Petersen</LastName>
                    <ForeName>Ann-Kristin</ForeName>
                    <Initials>AK</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sanna</LastName>
                    <ForeName>Serena</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Saxena</LastName>
                    <ForeName>Richa</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Service</LastName>
                    <ForeName>Susan K</ForeName>
                    <Initials>SK</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shah</LastName>
                    <ForeName>Sonia</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shungin</LastName>
                    <ForeName>Dmitry</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sidore</LastName>
                    <ForeName>Carlo</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Song</LastName>
                    <ForeName>Ci</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Strawbridge</LastName>
                    <ForeName>Rona J</ForeName>
                    <Initials>RJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Surakka</LastName>
                    <ForeName>Ida</ForeName>
                    <Initials>I</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tanaka</LastName>
                    <ForeName>Toshiko</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Teslovich</LastName>
                    <ForeName>Tanya M</ForeName>
                    <Initials>TM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Thorleifsson</LastName>
                    <ForeName>Gudmar</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Van den Herik</LastName>
                    <ForeName>Evita G</ForeName>
                    <Initials>EG</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Voight</LastName>
                    <ForeName>Benjamin F</ForeName>
                    <Initials>BF</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Volcik</LastName>
                    <ForeName>Kelly A</ForeName>
                    <Initials>KA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Waite</LastName>
                    <ForeName>Lindsay L</ForeName>
                    <Initials>LL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wong</LastName>
                    <ForeName>Andrew</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Ying</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Weihua</ForeName>
                    <Initials>W</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Absher</LastName>
                    <ForeName>Devin</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Asiki</LastName>
                    <ForeName>Gershim</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Barroso</LastName>
                    <ForeName>Inês</ForeName>
                    <Initials>I</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Been</LastName>
                    <ForeName>Latonya F</ForeName>
                    <Initials>LF</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bolton</LastName>
                    <ForeName>Jennifer L</ForeName>
                    <Initials>JL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bonnycastle</LastName>
                    <ForeName>Lori L</ForeName>
                    <Initials>LL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brambilla</LastName>
                    <ForeName>Paolo</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Burnett</LastName>
                    <ForeName>Mary S</ForeName>
                    <Initials>MS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cesana</LastName>
                    <ForeName>Giancarlo</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dimitriou</LastName>
                    <ForeName>Maria</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Doney</LastName>
                    <ForeName>Alex S F</ForeName>
                    <Initials>AS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Döring</LastName>
                    <ForeName>Angela</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Elliott</LastName>
                    <ForeName>Paul</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Epstein</LastName>
                    <ForeName>Stephen E</ForeName>
                    <Initials>SE</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Eyjolfsson</LastName>
                    <ForeName>Gudmundur Ingi</ForeName>
                    <Initials>GI</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gigante</LastName>
                    <ForeName>Bruna</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Goodarzi</LastName>
                    <ForeName>Mark O</ForeName>
                    <Initials>MO</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Grallert</LastName>
                    <ForeName>Harald</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gravito</LastName>
                    <ForeName>Martha L</ForeName>
                    <Initials>ML</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Groves</LastName>
                    <ForeName>Christopher J</ForeName>
                    <Initials>CJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hallmans</LastName>
                    <ForeName>Göran</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hartikainen</LastName>
                    <ForeName>Anna-Liisa</ForeName>
                    <Initials>AL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hayward</LastName>
                    <ForeName>Caroline</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hernandez</LastName>
                    <ForeName>Dena</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hicks</LastName>
                    <ForeName>Andrew A</ForeName>
                    <Initials>AA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Holm</LastName>
                    <ForeName>Hilma</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hung</LastName>
                    <ForeName>Yi-Jen</ForeName>
                    <Initials>YJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Illig</LastName>
                    <ForeName>Thomas</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jones</LastName>
                    <ForeName>Michelle R</ForeName>
                    <Initials>MR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kaleebu</LastName>
                    <ForeName>Pontiano</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kastelein</LastName>
                    <ForeName>John J P</ForeName>
                    <Initials>JJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Khaw</LastName>
                    <ForeName>Kay-Tee</ForeName>
                    <Initials>KT</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Eric</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Klopp</LastName>
                    <ForeName>Norman</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Komulainen</LastName>
                    <ForeName>Pirjo</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kumari</LastName>
                    <ForeName>Meena</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Langenberg</LastName>
                    <ForeName>Claudia</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lehtimäki</LastName>
                    <ForeName>Terho</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lin</LastName>
                    <ForeName>Shih-Yi</ForeName>
                    <Initials>SY</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lindström</LastName>
                    <ForeName>Jaana</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Loos</LastName>
                    <ForeName>Ruth J F</ForeName>
                    <Initials>RJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mach</LastName>
                    <ForeName>François</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McArdle</LastName>
                    <ForeName>Wendy L</ForeName>
                    <Initials>WL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Meisinger</LastName>
                    <ForeName>Christa</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mitchell</LastName>
                    <ForeName>Braxton D</ForeName>
                    <Initials>BD</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Müller</LastName>
                    <ForeName>Gabrielle</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nagaraja</LastName>
                    <ForeName>Ramaiah</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Narisu</LastName>
                    <ForeName>Narisu</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nieminen</LastName>
                    <ForeName>Tuomo V M</ForeName>
                    <Initials>TV</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nsubuga</LastName>
                    <ForeName>Rebecca N</ForeName>
                    <Initials>RN</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Olafsson</LastName>
                    <ForeName>Isleifur</ForeName>
                    <Initials>I</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ong</LastName>
                    <ForeName>Ken K</ForeName>
                    <Initials>KK</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Palotie</LastName>
                    <ForeName>Aarno</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Papamarkou</LastName>
                    <ForeName>Theodore</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pomilla</LastName>
                    <ForeName>Cristina</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pouta</LastName>
                    <ForeName>Anneli</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rader</LastName>
                    <ForeName>Daniel J</ForeName>
                    <Initials>DJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Reilly</LastName>
                    <ForeName>Muredach P</ForeName>
                    <Initials>MP</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ridker</LastName>
                    <ForeName>Paul M</ForeName>
                    <Initials>PM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rivadeneira</LastName>
                    <ForeName>Fernando</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rudan</LastName>
                    <ForeName>Igor</ForeName>
                    <Initials>I</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ruokonen</LastName>
                    <ForeName>Aimo</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Samani</LastName>
                    <ForeName>Nilesh</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Scharnagl</LastName>
                    <ForeName>Hubert</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Seeley</LastName>
                    <ForeName>Janet</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Silander</LastName>
                    <ForeName>Kaisa</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stančáková</LastName>
                    <ForeName>Alena</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stirrups</LastName>
                    <ForeName>Kathleen</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Swift</LastName>
                    <ForeName>Amy J</ForeName>
                    <Initials>AJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tiret</LastName>
                    <ForeName>Laurence</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Uitterlinden</LastName>
                    <ForeName>Andre G</ForeName>
                    <Initials>AG</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>van Pelt</LastName>
                    <ForeName>L Joost</ForeName>
                    <Initials>LJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vedantam</LastName>
                    <ForeName>Sailaja</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wainwright</LastName>
                    <ForeName>Nicholas</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wijmenga</LastName>
                    <ForeName>Cisca</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wild</LastName>
                    <ForeName>Sarah H</ForeName>
                    <Initials>SH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Willemsen</LastName>
                    <ForeName>Gonneke</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wilsgaard</LastName>
                    <ForeName>Tom</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wilson</LastName>
                    <ForeName>James F</ForeName>
                    <Initials>JF</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Young</LastName>
                    <ForeName>Elizabeth H</ForeName>
                    <Initials>EH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhao</LastName>
                    <ForeName>Jing Hua</ForeName>
                    <Initials>JH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Adair</LastName>
                    <ForeName>Linda S</ForeName>
                    <Initials>LS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Arveiler</LastName>
                    <ForeName>Dominique</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Assimes</LastName>
                    <ForeName>Themistocles L</ForeName>
                    <Initials>TL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bandinelli</LastName>
                    <ForeName>Stefania</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bennett</LastName>
                    <ForeName>Franklyn</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bochud</LastName>
                    <ForeName>Murielle</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Boehm</LastName>
                    <ForeName>Bernhard O</ForeName>
                    <Initials>BO</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Boomsma</LastName>
                    <ForeName>Dorret I</ForeName>
                    <Initials>DI</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Borecki</LastName>
                    <ForeName>Ingrid B</ForeName>
                    <Initials>IB</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bornstein</LastName>
                    <ForeName>Stefan R</ForeName>
                    <Initials>SR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bovet</LastName>
                    <ForeName>Pascal</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Burnier</LastName>
                    <ForeName>Michel</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Campbell</LastName>
                    <ForeName>Harry</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chakravarti</LastName>
                    <ForeName>Aravinda</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chambers</LastName>
                    <ForeName>John C</ForeName>
                    <Initials>JC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Yii-Der Ida</ForeName>
                    <Initials>YD</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Collins</LastName>
                    <ForeName>Francis S</ForeName>
                    <Initials>FS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cooper</LastName>
                    <ForeName>Richard S</ForeName>
                    <Initials>RS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Danesh</LastName>
                    <ForeName>John</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dedoussis</LastName>
                    <ForeName>George</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>de Faire</LastName>
                    <ForeName>Ulf</ForeName>
                    <Initials>U</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Feranil</LastName>
                    <ForeName>Alan B</ForeName>
                    <Initials>AB</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ferrières</LastName>
                    <ForeName>Jean</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ferrucci</LastName>
                    <ForeName>Luigi</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Freimer</LastName>
                    <ForeName>Nelson B</ForeName>
                    <Initials>NB</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gieger</LastName>
                    <ForeName>Christian</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Groop</LastName>
                    <ForeName>Leif C</ForeName>
                    <Initials>LC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gudnason</LastName>
                    <ForeName>Vilmundur</ForeName>
                    <Initials>V</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gyllensten</LastName>
                    <ForeName>Ulf</ForeName>
                    <Initials>U</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hamsten</LastName>
                    <ForeName>Anders</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Harris</LastName>
                    <ForeName>Tamara B</ForeName>
                    <Initials>TB</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hingorani</LastName>
                    <ForeName>Aroon</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hirschhorn</LastName>
                    <ForeName>Joel N</ForeName>
                    <Initials>JN</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hofman</LastName>
                    <ForeName>Albert</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hovingh</LastName>
                    <ForeName>G Kees</ForeName>
                    <Initials>GK</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hsiung</LastName>
                    <ForeName>Chao Agnes</ForeName>
                    <Initials>CA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Humphries</LastName>
                    <ForeName>Steve E</ForeName>
                    <Initials>SE</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hunt</LastName>
                    <ForeName>Steven C</ForeName>
                    <Initials>SC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hveem</LastName>
                    <ForeName>Kristian</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Iribarren</LastName>
                    <ForeName>Carlos</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Järvelin</LastName>
                    <ForeName>Marjo-Riitta</ForeName>
                    <Initials>MR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jula</LastName>
                    <ForeName>Antti</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kähönen</LastName>
                    <ForeName>Mika</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kaprio</LastName>
                    <ForeName>Jaakko</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kesäniemi</LastName>
                    <ForeName>Antero</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kivimaki</LastName>
                    <ForeName>Mika</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kooner</LastName>
                    <ForeName>Jaspal S</ForeName>
                    <Initials>JS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Koudstaal</LastName>
                    <ForeName>Peter J</ForeName>
                    <Initials>PJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Krauss</LastName>
                    <ForeName>Ronald M</ForeName>
                    <Initials>RM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kuh</LastName>
                    <ForeName>Diana</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kuusisto</LastName>
                    <ForeName>Johanna</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kyvik</LastName>
                    <ForeName>Kirsten O</ForeName>
                    <Initials>KO</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Laakso</LastName>
                    <ForeName>Markku</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lakka</LastName>
                    <ForeName>Timo A</ForeName>
                    <Initials>TA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lind</LastName>
                    <ForeName>Lars</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lindgren</LastName>
                    <ForeName>Cecilia M</ForeName>
                    <Initials>CM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Martin</LastName>
                    <ForeName>Nicholas G</ForeName>
                    <Initials>NG</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>März</LastName>
                    <ForeName>Winfried</ForeName>
                    <Initials>W</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McCarthy</LastName>
                    <ForeName>Mark I</ForeName>
                    <Initials>MI</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McKenzie</LastName>
                    <ForeName>Colin A</ForeName>
                    <Initials>CA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Meneton</LastName>
                    <ForeName>Pierre</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Metspalu</LastName>
                    <ForeName>Andres</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Moilanen</LastName>
                    <ForeName>Leena</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Morris</LastName>
                    <ForeName>Andrew D</ForeName>
                    <Initials>AD</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Munroe</LastName>
                    <ForeName>Patricia B</ForeName>
                    <Initials>PB</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Njølstad</LastName>
                    <ForeName>Inger</ForeName>
                    <Initials>I</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pedersen</LastName>
                    <ForeName>Nancy L</ForeName>
                    <Initials>NL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Power</LastName>
                    <ForeName>Chris</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pramstaller</LastName>
                    <ForeName>Peter P</ForeName>
                    <Initials>PP</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Price</LastName>
                    <ForeName>Jackie F</ForeName>
                    <Initials>JF</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Psaty</LastName>
                    <ForeName>Bruce M</ForeName>
                    <Initials>BM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Quertermous</LastName>
                    <ForeName>Thomas</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rauramaa</LastName>
                    <ForeName>Rainer</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Saleheen</LastName>
                    <ForeName>Danish</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Salomaa</LastName>
                    <ForeName>Veikko</ForeName>
                    <Initials>V</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sanghera</LastName>
                    <ForeName>Dharambir K</ForeName>
                    <Initials>DK</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Saramies</LastName>
                    <ForeName>Jouko</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schwarz</LastName>
                    <ForeName>Peter E H</ForeName>
                    <Initials>PE</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sheu</LastName>
                    <ForeName>Wayne H-H</ForeName>
                    <Initials>WH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shuldiner</LastName>
                    <ForeName>Alan R</ForeName>
                    <Initials>AR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Siegbahn</LastName>
                    <ForeName>Agneta</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Spector</LastName>
                    <ForeName>Tim D</ForeName>
                    <Initials>TD</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stefansson</LastName>
                    <ForeName>Kari</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Strachan</LastName>
                    <ForeName>David P</ForeName>
                    <Initials>DP</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tayo</LastName>
                    <ForeName>Bamidele O</ForeName>
                    <Initials>BO</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tremoli</LastName>
                    <ForeName>Elena</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tuomilehto</LastName>
                    <ForeName>Jaakko</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Uusitupa</LastName>
                    <ForeName>Matti</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>van Duijn</LastName>
                    <ForeName>Cornelia M</ForeName>
                    <Initials>CM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vollenweider</LastName>
                    <ForeName>Peter</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wallentin</LastName>
                    <ForeName>Lars</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wareham</LastName>
                    <ForeName>Nicholas J</ForeName>
                    <Initials>NJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Whitfield</LastName>
                    <ForeName>John B</ForeName>
                    <Initials>JB</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wolffenbuttel</LastName>
                    <ForeName>Bruce H R</ForeName>
                    <Initials>BH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Altshuler</LastName>
                    <ForeName>David</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ordovas</LastName>
                    <ForeName>Jose M</ForeName>
                    <Initials>JM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Boerwinkle</LastName>
                    <ForeName>Eric</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Palmer</LastName>
                    <ForeName>Colin N A</ForeName>
                    <Initials>CN</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Thorsteinsdottir</LastName>
                    <ForeName>Unnur</ForeName>
                    <Initials>U</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chasman</LastName>
                    <ForeName>Daniel I</ForeName>
                    <Initials>DI</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rotter</LastName>
                    <ForeName>Jerome I</ForeName>
                    <Initials>JI</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Franks</LastName>
                    <ForeName>Paul W</ForeName>
                    <Initials>PW</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ripatti</LastName>
                    <ForeName>Samuli</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cupples</LastName>
                    <ForeName>L Adrienne</ForeName>
                    <Initials>LA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sandhu</LastName>
                    <ForeName>Manjinder S</ForeName>
                    <Initials>MS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rich</LastName>
                    <ForeName>Stephen S</ForeName>
                    <Initials>SS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Boehnke</LastName>
                    <ForeName>Michael</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Deloukas</LastName>
                    <ForeName>Panos</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mohlke</LastName>
                    <ForeName>Karen L</ForeName>
                    <Initials>KL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ingelsson</LastName>
                    <ForeName>Erik</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Abecasis</LastName>
                    <ForeName>Goncalo R</ForeName>
                    <Initials>GR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Daly</LastName>
                    <ForeName>Mark J</ForeName>
                    <Initials>MJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Neale</LastName>
                    <ForeName>Benjamin M</ForeName>
                    <Initials>BM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kathiresan</LastName>
                    <ForeName>Sekar</ForeName>
                    <Initials>S</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>090532</GrantID>
                    <Agency>Wellcome Trust</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>100891</GrantID>
                    <Agency>Wellcome Trust</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>CZB/4/672</GrantID>
                    <Agency>Chief Scientist Office</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>CZB/4/710</GrantID>
                    <Agency>Chief Scientist Office</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>G0701863</GrantID>
                    <Agency>Medical Research Council</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>G0901213</GrantID>
                    <Agency>Medical Research Council</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>G1000143</GrantID>
                    <Agency>Medical Research Council</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>MC_U106179471</GrantID>
                    <Agency>Medical Research Council</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>MC_U106179472</GrantID>
                    <Agency>Medical Research Council</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>MC_U106188470</GrantID>
                    <Agency>Medical Research Council</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>MC_U123092720</GrantID>
                    <Agency>Medical Research Council</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>MC_U950080926</GrantID>
                    <Agency>Medical Research Council</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>MR/K013351/1</GrantID>
                    <Agency>Medical Research Council</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>MR/K013491/1</GrantID>
                    <Agency>Medical Research Council</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>MR/L003120/1</GrantID>
                    <Agency>Medical Research Council</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>NF-SI-0512-10135</GrantID>
                    <Agency>Department of Health</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>NF-SI-0512-10165</GrantID>
                    <Agency>Department of Health</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>P30 DK063491</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P30 DK072488</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P60 DK020541</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>PG/08/094/26019</GrantID>
                    <Agency>British Heart Foundation</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 DK072193</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 HL105756</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 HL107816</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 HL109946</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01HL107816</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>RG/08/014/24067</GrantID>
                    <Agency>British Heart Foundation</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>T32HL007208</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U01 HL069757</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>UL1 TR000124</GrantID>
                    <Acronym>TR</Acronym>
                    <Agency>NCATS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <Agency>Canadian Institutes of Health Research</Agency>
                    <Country>Canada</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2013</Year>
                <Month>10</Month>
                <Day>06</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Nat Genet</MedlineTA>
            <NlmUniqueID>9216904</NlmUniqueID>
            <ISSNLinking>1061-4036</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D008076">Cholesterol, HDL</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D008078">Cholesterol, LDL</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014280">Triglycerides</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS Med. 2007 Dec;4(12):e352</RefSource>
                <PMID Version="1">18076282</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Circulation. 2007 Jan 30;115(4):450-8</RefSource>
                <PMID Version="1">17190864</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2006 Mar 23;354(12):1264-72</RefSource>
                <PMID Version="1">16554528</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Lancet. 2005 Nov 26;366(9500):1849-61</RefSource>
                <PMID Version="1">16310551</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 1999 Aug 5;341(6):410-8</RefSource>
                <PMID Version="1">10438259</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Circulation. 1998 May 12;97(18):1837-47</RefSource>
                <PMID Version="1">9603539</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Lancet. 1997 May 17;349(9063):1436-42</RefSource>
                <PMID Version="1">9164317</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Epidemiol. 2004 Feb;33(1):30-42</RefSource>
                <PMID Version="1">15075143</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Epidemiol. 2003 Feb;32(1):1-22</RefSource>
                <PMID Version="1">12689998</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 2001 Oct 5;294(5540):169-73</RefSource>
                <PMID Version="1">11588264</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS Med. 2008 Aug 26;5(8):e177</RefSource>
                <PMID Version="1">18752343</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2010 Aug 5;466(7307):707-13</RefSource>
                <PMID Version="1">20686565</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Lancet. 2010 May 8;375(9726):1634-9</RefSource>
                <PMID Version="1">20452521</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2008 Feb;40(2):161-9</RefSource>
                <PMID Version="1">18193043</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2008 Feb;40(2):189-97</RefSource>
                <PMID Version="1">18193044</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2013 Nov;45(11):1274-83</RefSource>
                <PMID Version="1">24097068</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Am Coll Cardiol. 2013 Jan 29;61(4):427-36</RefSource>
                <PMID Version="1">23265341</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2013 Jan;45(1):25-33</RefSource>
                <PMID Version="1">23202125</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Lancet. 2012 Aug 11;380(9841):572-80</RefSource>
                <PMID Version="1">22607825</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2012 Jul 26;367(4):309-18</RefSource>
                <PMID Version="1">22686415</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Endocrinol Metab. 2012 Feb;97(2):E248-56</RefSource>
                <PMID Version="1">22090275</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Circulation. 2011 May 24;123(20):2292-333</RefSource>
                <PMID Version="1">21502576</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2011 Apr;43(4):333-8</RefSource>
                <PMID Version="1">21378990</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2010 Apr 29;362(17):1563-74</RefSource>
                <PMID Version="1">20228404</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2010 Oct 28;467(7319):1061-73</RefSource>
                <PMID Version="1">20981092</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Endocrinol Metab. 2010 Dec;95(12):E500-10</RefSource>
                <PMID Version="1">20826588</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Circ Cardiovasc Genet. 2010 Feb;3(1):109-17</RefSource>
                <PMID Version="1">20160203</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Genet. 2008 Feb;123(1):15-33</RefSource>
                <PMID Version="1">18038153</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>JAMA. 2008 Jun 4;299(21):2524-32</RefSource>
                <PMID Version="1">18523221</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 2008 Dec 12;322(5908):1702-5</RefSource>
                <PMID Version="1">19074352</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2009 Jan;41(1):56-65</RefSource>
                <PMID Version="1">19060906</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Endocrinol Metab. 2009 Apr;94(4):1264-73</RefSource>
                <PMID Version="1">19088157</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>JAMA. 2009 Nov 11;302(18):1993-2000</RefSource>
                <PMID Version="1">19903920</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001692">Biological Transport</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008076">Cholesterol, HDL</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008078">Cholesterol, LDL</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003324">Coronary Artery Disease</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000097">blood</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020641">Polymorphism, Single Nucleotide</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012307">Risk Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014280">Triglycerides</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000097">blood</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">NIHMS524704</OtherID>
        <OtherID Source="NLM">PMC3904346</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>2</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2013</Year>
                <Month>9</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2013</Year>
                <Month>10</Month>
                <Day>06</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>10</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>10</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>1</Month>
                <Day>9</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ng.2795</ArticleId>
            <ArticleId IdType="doi">10.1038/ng.2795</ArticleId>
            <ArticleId IdType="pubmed">24097064</ArticleId>
            <ArticleId IdType="pmc">PMC3904346</ArticleId>
            <ArticleId IdType="mid">NIHMS524704</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">16236146</PMID>
        <DateCreated>
            <Year>2005</Year>
            <Month>10</Month>
            <Day>20</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2005</Year>
            <Month>12</Month>
            <Day>07</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1742-7835</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>97</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2005</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Basic &amp; clinical pharmacology &amp; toxicology</Title>
                <ISOAbbreviation>Basic Clin. Pharmacol. Toxicol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Protective effects of different antioxidants and amrinone on vancomycin-induced nephrotoxicity.</ArticleTitle>
            <Pagination>
                <MedlinePgn>325-32</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>We have studied the effects of three antioxidants and amrinone, an inotropic agent, against vancomycin-induced nephrotoxicity in rats by investigating renal function and morphology. Thirty adult female Sprague Dawley rats (168-234 g) were divided into six groups. A saline-treated group served as control. The other five groups were treated for 7 days with vancomycin alone or in combination with alpha-lipoic acid, Ginkgo biloba extract 761, melatonin or amrinone. On day 8, all the rats were sacrificed by decapitation, kidney tissues were excised immediately and blood and kidney samples were collected. Blood urea and creatinine, kidney tissue malondialdehyde levels, and kidney superoxide dismutase and glutathione (GSH) peroxidase activities were measured. The kidneys were also examined for histological changes. Vancomycin administration led to increased urea, creatinine and malondialdehyde levels and decreased superoxide dismutase and GSH peroxidase activities. Co-administration of alpha-lipoic acid, Ginkgo biloba extract, melatonin or amrinone with vancomycin prevented the increases in the urea, creatinine and melondialdehyde levels and also resulted in higher superoxide dismutase and GSH peroxidase activities. The antioxidants and AMR improved the renal pathology compared to rats treated with vancomycin alone (P&lt;0.05). These results indicate that the three antioxidants and amrinone have potential protective effects against vancomycin-induced nephrotoxicity, which might in part be due to inhibition of free oxygen radical production. Amrinone was the most effective drug as judged on the basis of the pathological findings.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Celik</LastName>
                    <ForeName>Ilhami</ForeName>
                    <Initials>I</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical Microbiology and Infectious Diseases, Faculty of Medicine, Firat University, 23119 Elazig, Turkey. ilhamicelik@hotmail.com</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cihangiroglu</LastName>
                    <ForeName>Mustafa</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ilhan</LastName>
                    <ForeName>Nevin</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Akpolat</LastName>
                    <ForeName>Nusret</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Akbulut</LastName>
                    <ForeName>H Handan</ForeName>
                    <Initials>HH</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Denmark</Country>
            <MedlineTA>Basic Clin Pharmacol Toxicol</MedlineTA>
            <NlmUniqueID>101208422</NlmUniqueID>
            <ISSNLinking>1742-7835</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D005609">Free Radicals</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010726">Phosphodiesterase Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017392">Thiobarbituric Acid Reactive Substances</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>4Y8F71G49Q</RegistryNumber>
                <NameOfSubstance UI="D008315">Malondialdehyde</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>6Q205EH1VU</RegistryNumber>
                <NameOfSubstance UI="D014640">Vancomycin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>73Y7P0K73Y</RegistryNumber>
                <NameOfSubstance UI="D008063">Thioctic Acid</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.11.1.9</RegistryNumber>
                <NameOfSubstance UI="D005979">Glutathione Peroxidase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.15.1.1</RegistryNumber>
                <NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>JL5DK93RCL</RegistryNumber>
                <NameOfSubstance UI="D008550">Melatonin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>JUT23379TN</RegistryNumber>
                <NameOfSubstance UI="D000676">Amrinone</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000676">Amrinone</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000900">Anti-Bacterial Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000975">Antioxidants</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005609">Free Radicals</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020441">Ginkgo biloba</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005979">Glutathione Peroxidase</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007672">Kidney Cortex</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007674">Kidney Diseases</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007677">Kidney Function Tests</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008315">Malondialdehyde</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008550">Melatonin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010726">Phosphodiesterase Inhibitors</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017207">Rats, Sprague-Dawley</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013482">Superoxide Dismutase</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017392">Thiobarbituric Acid Reactive Substances</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008063">Thioctic Acid</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014640">Vancomycin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2005</Year>
                <Month>10</Month>
                <Day>21</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2005</Year>
                <Month>12</Month>
                <Day>13</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2005</Year>
                <Month>10</Month>
                <Day>21</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">PTOpto_153</ArticleId>
            <ArticleId IdType="doi">10.1111/j.1742-7843.2005.pto_153.x</ArticleId>
            <ArticleId IdType="pubmed">16236146</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">9644553</PMID>
        <DateCreated>
            <Year>1998</Year>
            <Month>07</Month>
            <Day>23</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1998</Year>
            <Month>07</Month>
            <Day>23</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0365-9615</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>125</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>1998</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Biulleten' eksperimental'noĭ biologii i meditsiny</Title>
                <ISOAbbreviation>Biull Eksp Biol Med</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[Effect of calcium channel blocker nifedipine on anxiety and seizure manifestations of abstinence syndrome in rats after withdrawal of long-term diazepam administration].</ArticleTitle>
            <Pagination>
                <MedlinePgn>538-40</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Garibova</LastName>
                    <ForeName>T L</ForeName>
                    <Initials>TL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Val'dman</LastName>
                    <ForeName>E A</ForeName>
                    <Initials>EA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Voronina</LastName>
                    <ForeName>T A</ForeName>
                    <Initials>TA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kraĭneva</LastName>
                    <ForeName>V A</ForeName>
                    <Initials>VA</Initials>
                </Author>
            </AuthorList>
            <Language>rus</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <VernacularTitle>Vliianie blokatora kal'tsievykh kanalov nifedipina na trevogu i sudorozhnye proiavleniia abstinentnogo sindroma u krys posle otmeny dlitel'nogo vvedeniia diazepama.</VernacularTitle>
        </Article>
        <MedlineJournalInfo>
            <Country>RUSSIA</Country>
            <MedlineTA>Biull Eksp Biol Med</MedlineTA>
            <NlmUniqueID>0370627</NlmUniqueID>
            <ISSNLinking>0365-9615</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014151">Anti-Anxiety Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D002121">Calcium Channel Blockers</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D015220">Calcium Channels</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D003292">Convulsants</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>I9ZF7L6G2L</RegistryNumber>
                <NameOfSubstance UI="D009543">Nifedipine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>Q3JTX2Q7TU</RegistryNumber>
                <NameOfSubstance UI="D003975">Diazepam</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>WM5Z385K7T</RegistryNumber>
                <NameOfSubstance UI="D010433">Pentylenetetrazole</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000222">Adaptation, Physiological</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014151">Anti-Anxiety Agents</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001007">Anxiety</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002121">Calcium Channel Blockers</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015220">Calcium Channels</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003292">Convulsants</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003975">Diazepam</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007696">Kindling, Neurologic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009543">Nifedipine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010433">Pentylenetetrazole</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017208">Rats, Wistar</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012640">Seizures</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013375">Substance Withdrawal Syndrome</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019966">Substance-Related Disorders</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1998</Year>
                <Month>6</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1998</Year>
                <Month>6</Month>
                <Day>30</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1998</Year>
                <Month>6</Month>
                <Day>30</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9644553</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">1379664</PMID>
        <DateCreated>
            <Year>1992</Year>
            <Month>09</Month>
            <Day>08</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1992</Year>
            <Month>09</Month>
            <Day>08</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0023-852X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>102</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>1992</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The Laryngoscope</Title>
                <ISOAbbreviation>Laryngoscope</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Treatment of recurrent head and neck cancer with cisplatin and 5-fluorouracil vs. the same plus bleomycin and methotrexate.</ArticleTitle>
            <Pagination>
                <MedlinePgn>901-6</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>A prospective randomized trial of 62 patients with recurrent squamous cell carcinoma of the head and neck was conducted to compare the effectiveness of our standard chemotherapy program with that of our test regimen. The standard chemotherapy regimen consisted of cisplatin 80 mg/M2 on day 1 followed by 5-fluorouracil 800 mg/M2 days 2 through 6. Our test regimen consisted of the same two drugs plus 15 U bleomycin on day 1 and methotrexate 100 mg/M2 on day 16 followed in 24 hours with 15 mg leucovorin every 6 hours for six doses. One patient in each arm of the study was not evaluated. Among 29 patients receiving the two-drug regimen, there was 1 complete response and 10 partial responses (38% response rate). Among 31 patients receiving the four-drug regimen, there were 3 complete responses and 16 partial responses (61% response rate; two vs. four-drug regimen, P = .06). The failure-free survival in the four-drug group was better than the two-drug group, median 4.5 vs. 2.3 months (P = .02). The overall survival for both groups was the same (median of 7.8 months). A detailed analysis of toxicity did not reveal any important differences between the two regimens. The addition of bleomycin and methotrexate to our cisplatin and 5-fluorouracil regimen resulted in an increase in effectiveness without adding toxicity.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Amrein</LastName>
                    <ForeName>P C</ForeName>
                    <Initials>PC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Massachusetts General Hospital, Boston 02114.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fabian</LastName>
                    <ForeName>R L</ForeName>
                    <Initials>RL</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016430">Clinical Trial</PublicationType>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Laryngoscope</MedlineTA>
            <NlmUniqueID>8607378</NlmUniqueID>
            <ISSNLinking>0023-852X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>11056-06-7</RegistryNumber>
                <NameOfSubstance UI="D001761">Bleomycin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>Q20Q21Q62J</RegistryNumber>
                <NameOfSubstance UI="D002945">Cisplatin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>U3P01618RT</RegistryNumber>
                <NameOfSubstance UI="D005472">Fluorouracil</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>YL5FZ2Y5U1</RegistryNumber>
                <NameOfSubstance UI="D008727">Methotrexate</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001761">Bleomycin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002294">Carcinoma, Squamous Cell</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002945">Cisplatin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004334">Drug Administration Schedule</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004432">Ear, Middle</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005472">Fluorouracil</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006258">Head and Neck Neoplasms</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006973">Hypertension</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007668">Kidney</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007970">Leukopenia</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008727">Methotrexate</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009325">Nausea</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009364">Neoplasm Recurrence, Local</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012074">Remission Induction</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015996">Survival Rate</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1992</Year>
                <Month>8</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1992</Year>
                <Month>8</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1992</Year>
                <Month>8</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">1379664</ArticleId>
            <ArticleId IdType="doi">10.1288/00005537-199208000-00010</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">8490596</PMID>
        <DateCreated>
            <Year>1993</Year>
            <Month>06</Month>
            <Day>11</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1993</Year>
            <Month>06</Month>
            <Day>11</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1064-1963</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>15</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>1993</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical and experimental hypertension (New York, N.Y. : 1993)</Title>
                <ISOAbbreviation>Clin. Exp. Hypertens.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Effect of nicardipine treatment on carbohydrate and lipoprotein metabolism in patients with hypertension.</ArticleTitle>
            <Pagination>
                <MedlinePgn>557-73</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>This study evaluated the effect of nicardipine, calcium channel blocker, monotherapy on blood pressure and metabolic changes. Various aspect of carbohydrate and lipoprotein metabolism were studied before and after 12 weeks of nicardipine treatment in 23 patients with mild to moderate essential hypertension. Nicardipine was well tolerated and induced a significant decrease (p &lt; 0.001) in both systolic and diastolic blood pressure without any changes in heart rate. Plasma levels of fasting glucose, insulin, C-peptide and hemoglobin A1c, hepatic extraction of insulin were similar following nicardipine treatment. Plasma glucose and insulin responses to an oral glucose challenge did not change in association with nicardipine therapy. Although high density lipoprotein (HDL) cholesterol concentration increased slightly, it did not reach statistical significance. Total cholesterol and low density lipoprotein (LDL) cholesterol levels also increased insignificantly. LDL triglyceride and very low density lipoprotein (VLDL) triglyceride concentrations were higher marginally, which resulted in slightly but insignificantly increase in total triglyceride concentration in association with nicardipine monotherapy for 12 weeks. In conclusion, treatment of patients with mild to moderate hypertension with nicardipine led to lower blood pressure effectively while had no significant influence on carbohydrate and lipoprotein metabolism.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>D J</ForeName>
                    <Initials>DJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Tri-Service General Hospital, Taipei, Taiwan, ROC.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shen</LastName>
                    <ForeName>D C</ForeName>
                    <Initials>DC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sheu</LastName>
                    <ForeName>W H</ForeName>
                    <Initials>WH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chu</LastName>
                    <ForeName>N F</ForeName>
                    <Initials>NF</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fuh</LastName>
                    <ForeName>M M</ForeName>
                    <Initials>MM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>L M</ForeName>
                    <Initials>LM</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Clin Exp Hypertens</MedlineTA>
            <NlmUniqueID>9305929</NlmUniqueID>
            <ISSNLinking>1064-1963</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007328">Insulin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D008074">Lipoproteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>CZ5312222S</RegistryNumber>
                <NameOfSubstance UI="D009529">Nicardipine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>IY9XDZ35W2</RegistryNumber>
                <NameOfSubstance UI="D005947">Glucose</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001786">Blood Glucose</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D050260">Carbohydrate Metabolism</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005215">Fasting</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005947">Glucose</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005951">Glucose Tolerance Test</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006973">Hypertension</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000097">blood</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007328">Insulin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008074">Lipoproteins</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009529">Nicardipine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009994">Osmolar Concentration</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1993</Year>
                <Month>5</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1993</Year>
                <Month>5</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1993</Year>
                <Month>5</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8490596</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">18031782</PMID>
        <DateCreated>
            <Year>2008</Year>
            <Month>03</Month>
            <Day>03</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2008</Year>
            <Month>04</Month>
            <Day>01</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>09</Month>
            <Day>04</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">0041-008X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>227</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2008</Year>
                        <Month>Feb</Month>
                        <Day>15</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Toxicology and applied pharmacology</Title>
                <ISOAbbreviation>Toxicol. Appl. Pharmacol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Mechanism of chloroform-induced renal toxicity: non-involvement of hepatic cytochrome P450-dependent metabolism.</ArticleTitle>
            <Pagination>
                <MedlinePgn>48-55</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Chloroform causes hepatic and renal toxicity in a number of species. In vitro studies have indicated that chloroform can be metabolized by P450 enzymes in the kidney to nephrotoxic intermediate, although direct in vivo evidence for the role of renal P450 in the nephrotoxicity has not been reported. This study was to determine whether chloroform renal toxicity persists in a mouse model with a liver-specific deletion of the P450 reductase (Cpr) gene (liver-Cpr-null). Chloroform-induced renal toxicity and chloroform tissue levels were compared between the liver-Cpr-null and wild-type mice at 24 h following differing doses of chloroform. At a chloroform dose of 150 mg/kg, the levels of blood urea nitrogen (BUN) were five times higher in the exposed group than in the vehicle-treated one for the liver-Cpr-null mice, but they were only slightly higher in the exposed group than in the vehicle-treated group for the wild-type mice. Severe lesions were found in the kidney of the liver-Cpr-null mice, while only mild lesions were found in the wild-type mice. At a chloroform dose of 300 mg/kg, severe kidney lesions were observed in both strains, yet the BUN levels were still higher in the liver-Cpr-null than in the wild-type mice. Higher chloroform levels were found in the tissues of the liver-Cpr-null mice. These findings indicated that loss of hepatic P450-dependent chloroform metabolism does not protect against chloroform-induced renal toxicity, suggesting that renal P450 enzymes play an essential role in chloroform renal toxicity.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Fang</LastName>
                    <ForeName>Cheng</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Wadsworth Center, New York State Department of Health, Albany, NY 12201-0509, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Behr</LastName>
                    <ForeName>Melissa</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xie</LastName>
                    <ForeName>Fang</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lu</LastName>
                    <ForeName>Shijun</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Doret</LastName>
                    <ForeName>Meghan</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Luo</LastName>
                    <ForeName>Hongxiu</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Weizhu</ForeName>
                    <Initials>W</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Aldous</LastName>
                    <ForeName>Kenneth</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ding</LastName>
                    <ForeName>Xinxin</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gu</LastName>
                    <ForeName>Jun</ForeName>
                    <Initials>J</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>AG026329</GrantID>
                    <Acronym>AG</Acronym>
                    <Agency>NIA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>CA092596</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>ES07462</GrantID>
                    <Acronym>ES</Acronym>
                    <Agency>NIEHS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R03 AG026329-01</GrantID>
                    <Acronym>AG</Acronym>
                    <Agency>NIA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R03 AG026329-02</GrantID>
                    <Acronym>AG</Acronym>
                    <Agency>NIA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2007</Year>
                <Month>10</Month>
                <Day>23</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Toxicol Appl Pharmacol</MedlineTA>
            <NlmUniqueID>0416575</NlmUniqueID>
            <ISSNLinking>0041-008X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>7V31YC746X</RegistryNumber>
                <NameOfSubstance UI="D002725">Chloroform</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9035-51-2</RegistryNumber>
                <NameOfSubstance UI="D003577">Cytochrome P-450 Enzyme System</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Appl Pharmacol. 1987 Nov;91(2):266-73</RefSource>
                <PMID Version="1">3118512</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Adv Enzymol Relat Areas Mol Biol. 1987;60:35-87</RefSource>
                <PMID Version="1">3310532</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Xenobiotica. 1992 Sep-Oct;22(9-10):1135-45</RefSource>
                <PMID Version="1">1441604</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Fundam Appl Toxicol. 1993 Apr;20(3):302-15</RefSource>
                <PMID Version="1">8504904</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Fundam Appl Toxicol. 1997 Nov;40(1):101-10</RefSource>
                <PMID Version="1">9398492</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Lett. 2006 Mar 15;162(1):111-7</RefSource>
                <PMID Version="1">16343823</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Appl Pharmacol. 2006 Jun 15;213(3):267-81</RefSource>
                <PMID Version="1">16630638</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Chromatogr A. 2007 Jan 12;1139(1):27-35</RefSource>
                <PMID Version="1">17109874</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pharmacol Exp Ther. 2007 Apr;321(1):9-17</RefSource>
                <PMID Version="1">17218484</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 2007 Aug 15;67(16):7825-32</RefSource>
                <PMID Version="1">17699788</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Drug Metab Dispos. 2007 Sep;35(9):1617-23</RefSource>
                <PMID Version="1">17567730</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Pathol. 1998 Jan-Feb;26(1):18-25</RefSource>
                <PMID Version="1">9502382</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Drug Metab Dispos. 1999 Apr;27(4):542-8</RefSource>
                <PMID Version="1">10101150</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 1999 Jun 18;274(25):17777-88</RefSource>
                <PMID Version="1">10364221</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Appl Pharmacol. 1999 Oct 15;160(2):120-6</RefSource>
                <PMID Version="1">10527910</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 1964 Jul;239:2370-8</RefSource>
                <PMID Version="1">14209971</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Pharmacol. 2005 Mar;67(3):623-30</RefSource>
                <PMID Version="1">15550675</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 2005 May 15;65(10):4211-7</RefSource>
                <PMID Version="1">15899812</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Lett. 2001 Oct 15;124(1-3):21-36</RefSource>
                <PMID Version="1">11684355</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Physiol Renal Physiol. 2003 Jan;284(1):F95-102</RefSource>
                <PMID Version="1">12388424</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Annu Rev Pharmacol Toxicol. 2003;43:149-73</RefSource>
                <PMID Version="1">12171978</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2003 Apr 11;278(15):13480-6</RefSource>
                <PMID Version="1">12566435</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2003 Jul 11;278(28):25895-901</RefSource>
                <PMID Version="1">12697746</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Semin Nephrol. 2003 Sep;23(5):500-8</RefSource>
                <PMID Version="1">13680539</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem Biophys Res Commun. 1977 Dec 7;79(3):684-91</RefSource>
                <PMID Version="1">597296</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 1980 Jun 27;208(4451):1473-5</RefSource>
                <PMID Version="1">6770464</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Res Commun Chem Pathol Pharmacol. 1981 Jan;31(1):99-110</RefSource>
                <PMID Version="1">7255876</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Appl Pharmacol. 1984 Jan;72(1):159-68</RefSource>
                <PMID Version="1">6143425</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Appl Pharmacol. 1984 May;73(3):511-24</RefSource>
                <PMID Version="1">6719466</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Drug Metab Dispos. 1984 May-Jun;12(3):304-8</RefSource>
                <PMID Version="1">6145557</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 1991 Jul 25;266(21):13469-72</RefSource>
                <PMID Version="1">1856184</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001682">Biological Availability</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002725">Chloroform</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000493">pharmacokinetics</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003577">Cytochrome P-450 Enzyme System</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007150">Immunohistochemistry</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007668">Kidney</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008099">Liver</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">NIHMS40774</OtherID>
        <OtherID Source="NLM">PMC2274901</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2007</Year>
                <Month>8</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2007</Year>
                <Month>10</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2007</Year>
                <Month>10</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2007</Year>
                <Month>10</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2007</Year>
                <Month>11</Month>
                <Day>23</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2008</Year>
                <Month>4</Month>
                <Day>2</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2007</Year>
                <Month>11</Month>
                <Day>23</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0041-008X(07)00465-6</ArticleId>
            <ArticleId IdType="doi">10.1016/j.taap.2007.10.014</ArticleId>
            <ArticleId IdType="pubmed">18031782</ArticleId>
            <ArticleId IdType="pmc">PMC2274901</ArticleId>
            <ArticleId IdType="mid">NIHMS40774</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">2522601</PMID>
        <DateCreated>
            <Year>1989</Year>
            <Month>04</Month>
            <Day>26</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1989</Year>
            <Month>04</Month>
            <Day>26</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0028-3878</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>39</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>1989</Year>
                        <Month>Mar</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Neurology</Title>
                <ISOAbbreviation>Neurology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Hypersensitivity to carbamazepine presenting with a leukemoid reaction, eosinophilia, erythroderma, and renal failure.</ArticleTitle>
            <Pagination>
                <MedlinePgn>436-8</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma, a severe leukemoid reaction, eosinophilia, hyponatremia, and renal failure. This is the first report of such an unusual reaction to carbamazepine.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ray-Chaudhuri</LastName>
                    <ForeName>K</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Neurology, Leicester Royal Infirmary, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pye</LastName>
                    <ForeName>I F</ForeName>
                    <Initials>IF</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Boggild</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Neurology</MedlineTA>
            <NlmUniqueID>0401060</NlmUniqueID>
            <ISSNLinking>0028-3878</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>33CM23913M</RegistryNumber>
                <NameOfSubstance UI="D002220">Carbamazepine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002220">Carbamazepine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003873">Dermatitis, Exfoliative</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D004342">Drug Hypersensitivity</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004802">Eosinophilia</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007674">Kidney Diseases</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007955">Leukemoid Reaction</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1989</Year>
                <Month>3</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1989</Year>
                <Month>3</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1989</Year>
                <Month>3</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2522601</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">21683774</PMID>
        <DateCreated>
            <Year>2011</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2011</Year>
            <Month>10</Month>
            <Day>28</Day>
        </DateCompleted>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1879-3169</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>206</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2011</Year>
                        <Month>Sep</Month>
                        <Day>25</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Toxicology letters</Title>
                <ISOAbbreviation>Toxicol. Lett.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Organophosphate hydrolases as catalytic bioscavengers of organophosphorus nerve agents.</ArticleTitle>
            <Pagination>
                <MedlinePgn>14-23</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.toxlet.2011.05.1041</ELocationID>
            <Abstract>
                <AbstractText>Bioscavengers are molecules able to neutralize neurotoxic organophosphorus compounds (OP) before they can reach their biological target. Human butyrylcholinesterase (hBChE) is a natural bioscavenger each molecule of enzyme neutralizing one molecule of OP. The amount of natural enzyme is insufficient to achieve good protection. Thus, different strategies have been envisioned. The most straightforward consists in injecting a large dose of highly purified natural hBChE to increase the amount of bioscavenger in the bloodstream. This proved to be successful for protection against lethal doses of soman and VX but remains expensive. An improved strategy is to regenerate prophylactic cholinesterases (ChE) by administration of reactivators after exposure. But broad-spectrum efficient reactivators are still lacking, especially for inhibited hBChE. Cholinesterase mutants capable of reactivating spontaneously are another option. The G117H hBChE mutant has been a prototype. We present here the Y124H/Y72D mutant of human acetylcholinesterase; its spontaneous reactivation rate after V-agent inhibition is increased up to 110 fold. Catalytic bioscavengers, enzymes capable of hydrolyzing OP, present the best alternative. Mesophilic bacterial phosphotriesterase (PTE) is a candidate with good catalytic efficiency. Its enantioselectivity has been enhanced against the most potent OP isomers by rational design. We show that PEGylation of this enzyme improves its mean residence time in the rat blood stream 24-fold and its bioavailability 120-fold. Immunogenic issues remain to be solved. Human paraoxonase 1 (hPON1) is another promising candidate. However, its main drawback is that its phosphotriesterase activity is highly dependent on its environment. Recent progress has been made using a mammalian chimera of PON1, but we provide here additional data showing that this chimera is biochemically different from hPON1. Besides, the chimera is expected to suffer from immunogenic issues. Thus, we stress that interest for hPON1 must not fade away, and in particular, the 3D structure of the hPON1 eventually in complex with OP has to be solved.</AbstractText>
                <CopyrightInformation>Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Trovaslet-Leroy</LastName>
                    <ForeName>Marie</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Département de Toxicologie, Institut de Recherches Biomédicales des Armées, 38700 La Tronche, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Musilova</LastName>
                    <ForeName>Lucie</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Renault</LastName>
                    <ForeName>Frédérique</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brazzolotto</LastName>
                    <ForeName>Xavier</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Misik</LastName>
                    <ForeName>Jan</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Novotny</LastName>
                    <ForeName>Ladislav</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Froment</LastName>
                    <ForeName>Marie-Thérèse</ForeName>
                    <Initials>MT</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gillon</LastName>
                    <ForeName>Emilie</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Loiodice</LastName>
                    <ForeName>Mélanie</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Verdier</LastName>
                    <ForeName>Laurent</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Masson</LastName>
                    <ForeName>Patrick</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rochu</LastName>
                    <ForeName>Daniel</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jun</LastName>
                    <ForeName>Daniel</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nachon</LastName>
                    <ForeName>Florian</ForeName>
                    <Initials>F</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2011</Year>
                <Month>06</Month>
                <Day>12</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Toxicol Lett</MedlineTA>
            <NlmUniqueID>7709027</NlmUniqueID>
            <ISSNLinking>0378-4274</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D002619">Chemical Warfare Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D002801">Cholinesterase Reactivators</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009943">Organophosphorus Compounds</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.1.1.7</RegistryNumber>
                <NameOfSubstance UI="D000110">Acetylcholinesterase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.1.8.-</RegistryNumber>
                <NameOfSubstance UI="D044345">Phosphoric Triester Hydrolases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.1.8.1</RegistryNumber>
                <NameOfSubstance UI="D043303">Aryldialkylphosphatase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.1.8.1</RegistryNumber>
                <NameOfSubstance UI="C468406">PON1 protein, human</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000110">Acetylcholinesterase</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D043303">Aryldialkylphosphatase</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D055162">Biocatalysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016466">CHO Cells</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002619">Chemical Warfare Agents</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002801">Cholinesterase Reactivators</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003001">Cloning, Molecular</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006224">Cricetinae</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003412">Cricetulus</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004355">Drug Stability</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006868">Hydrolysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009154">Mutation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009943">Organophosphorus Compounds</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D044345">Phosphoric Triester Hydrolases</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017208">Rats, Wistar</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013379">Substrate Specificity</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014162">Transfection</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2011</Year>
                <Month>5</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2011</Year>
                <Month>5</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2011</Year>
                <Month>5</Month>
                <Day>31</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2011</Year>
                <Month>6</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2011</Year>
                <Month>6</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2011</Year>
                <Month>6</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2011</Year>
                <Month>10</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0378-4274(11)01259-8</ArticleId>
            <ArticleId IdType="doi">10.1016/j.toxlet.2011.05.1041</ArticleId>
            <ArticleId IdType="pubmed">21683774</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">2943245</PMID>
        <DateCreated>
            <Year>1986</Year>
            <Month>09</Month>
            <Day>16</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1986</Year>
            <Month>09</Month>
            <Day>16</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0020-3785</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>56</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <MedlineDate>1986 Jan-Feb</MedlineDate>
                    </PubDate>
                </JournalIssue>
                <Title>Archivos del Instituto de Cardiología de México</Title>
                <ISOAbbreviation>Arch Inst Cardiol Mex</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[Pharmacologic study of a semisynthetic digitalis derivative lacking the hydroxyl group on position 14 of the steroid nucleus].</ArticleTitle>
            <Pagination>
                <MedlinePgn>5-12</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>All natural cardiac glycosides (CG) have a hydroxyl (OH) group attached to carbon 14 (C 14) of the steroid nucleus which has been considered important for their pharmacological action. To investigate the relation between chemical structure and biological activity of CG, we studied the cardiac effects of a semisynthetic derivative if gluco-digitoxigenin that lacks the C 14 hydroxyl group; the compound was named Dig-3 and corresponds to the number of a series of semisynthetic glycosides being studied. On the failing heart of the Starling's heart-lung preparation Dig-3 reverts experimental cardiac failure. Electrophysiological experiments in anesthetized dogs (morphine chloralose) have shown that Dig-3 shortens the functional refractory period of the ordinary atrial myocardium (OAM), and lengthens that of the specialized atrial tissue (SAT). The basal excitability is reduced in both tissues, however OAM is more susceptible to Dig-3 action. The conduction velocity of impulses in SAT diminishes 50% with one tenth of the lethal dose (LD) of Dig-3 whereas in the OAM, an equivalent decrease is achieved with 60% of LD. A-V dissociation induced by the infusion of toxic doses of Dig-3 reverted to sinus rhythm in about 6 min after the administration was stopped. We conclude that the presence of the OH group attached to C 14 of digitalis molecule does not constitute a structural requirement for the preservation of its inotropic and electrophysiological actions on the heart, although its potency is greatly diminished.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Alvarado</LastName>
                    <ForeName>J L</ForeName>
                    <Initials>JL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pastelín</LastName>
                    <ForeName>G</ForeName>
                    <Initials>G</Initials>
                </Author>
            </AuthorList>
            <Language>spa</Language>
            <PublicationTypeList>
                <PublicationType UI="D004740">English Abstract</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <VernacularTitle>Estudio farmacológico de un digitálico semisintético desprovisto del grupo oxhidrilo en la posición 14 del núcleo esteroideo.</VernacularTitle>
        </Article>
        <MedlineJournalInfo>
            <Country>MEXICO</Country>
            <MedlineTA>Arch Inst Cardiol Mex</MedlineTA>
            <NlmUniqueID>0400463</NlmUniqueID>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>102492-19-3</RegistryNumber>
                <NameOfSubstance UI="C048858">14-dehydroxy-3-glucodigitoxigenin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>5ACL011P69</RegistryNumber>
                <NameOfSubstance UI="D010042">Ouabain</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>E90NZP2L9U</RegistryNumber>
                <NameOfSubstance UI="D004074">Digitoxin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004074">Digitoxin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000138">chemical synthesis</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004285">Dogs</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006325">Heart Atria</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006333">Heart Failure</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009200">Myocardial Contraction</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010042">Ouabain</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012032">Refractory Period, Electrophysiological</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013268">Stimulation, Chemical</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013329">Structure-Activity Relationship</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014693">Ventricular Fibrillation</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1986</Year>
                <Month>1</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1986</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1986</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2943245</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">12690208</PMID>
        <DateCreated>
            <Year>2003</Year>
            <Month>05</Month>
            <Day>05</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2003</Year>
            <Month>06</Month>
            <Day>30</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2004</Year>
            <Month>11</Month>
            <Day>17</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1524-4628</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>34</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2003</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Stroke; a journal of cerebral circulation</Title>
                <ISOAbbreviation>Stroke</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Danger of treatment protocols.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e19</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Cucchiara</LastName>
                    <ForeName>Brett</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Messé</LastName>
                    <ForeName>Steven</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kasner</LastName>
                    <ForeName>Scott E</ForeName>
                    <Initials>SE</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016422">Letter</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2003</Year>
                <Month>04</Month>
                <Day>10</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Stroke</MedlineTA>
            <NlmUniqueID>0235266</NlmUniqueID>
            <ISSNLinking>0039-2499</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D005343">Fibrinolytic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9005-49-6</RegistryNumber>
                <NameOfSubstance UI="D006493">Heparin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.4.21.68</RegistryNumber>
                <NameOfSubstance UI="D010959">Tissue Plasminogen Activator</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000925">Anticoagulants</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000744">contraindications</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001037">Aphasia</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002545">Brain Ischemia</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000451">nursing</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000530">radiography</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002543">Cerebral Hemorrhage</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000530">radiography</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002544">Cerebral Infarction</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000530">radiography</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D002985">Clinical Protocols</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005343">Fibrinolytic Agents</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019983">Guideline Adherence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006493">Heparin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000744">contraindications</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D008508">Medication Errors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010291">Paresis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010296">Parietal Lobe</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000098">blood supply</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000530">radiography</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013702">Temporal Lobe</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000098">blood supply</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000530">radiography</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013788">Thalamus</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000098">blood supply</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000530">radiography</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015912">Thrombolytic Therapy</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010959">Tissue Plasminogen Activator</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014057">Tomography, X-Ray Computed</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2003</Year>
                <Month>4</Month>
                <Day>12</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2003</Year>
                <Month>7</Month>
                <Day>2</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2003</Year>
                <Month>Apr</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2003</Year>
                <Month>4</Month>
                <Day>12</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12690208</ArticleId>
            <ArticleId IdType="doi">10.1161/01.STR.0000069436.07686.CA</ArticleId>
            <ArticleId IdType="pii">01.STR.0000069436.07686.CA</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">18319729</PMID>
        <DateCreated>
            <Year>2008</Year>
            <Month>05</Month>
            <Day>23</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2008</Year>
            <Month>07</Month>
            <Day>18</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">0271-678X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>28</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2008</Year>
                        <Month>Jun</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</Title>
                <ISOAbbreviation>J. Cereb. Blood Flow Metab.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Aspirin resistance is more common in lacunar strokes than embolic strokes and is related to stroke severity.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1196-203</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/jcbfm.2008.9</ELocationID>
            <Abstract>
                <AbstractText>The aim of this study was to investigate the relationship between aspirin resistance, ischaemic stroke subtype, stroke severity, and inflammatory cytokines. Aspirin resistance was assessed by thrombelastography in 45 people with ischaemic stroke and 25 controls. Plasma interleukin (IL)-6 was measured. Stroke severity was assessed using the modified Rankin scale and National Institute of Health Stroke Score within 72 h of stroke. Aspirin resistance was more common in the stroke than the control group (67% versus 40%, P=0.028), and within the stroke group the aspirin-resistant group had a higher Rankin score (4.0 versus 2.0, P=0.013). Aspirin resistance was greater in lacunar than embolic strokes (platelet activation 79% versus 59%, P=0.020). The stroke aspirin-resistant group had higher levels of IL-6 than the stroke aspirin-sensitive group (2.4+/-1 versus 1.8+/-0.9 ng/mL, P=0.037). Using multivariate analysis, we examined the interrelationships between aspirin resistance, IL-6, and stroke severity. These analyses showed that IL-6 was independently associated with stroke severity as the outcome (B=3.738, P=0.036), and aspirin resistance was independently associated with IL-6 (B=0.765, P=0.005) as the outcome. In conclusion, aspirin resistance is related to stroke severity and aspirin resistance is more common in lacunar strokes than embolic strokes.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Englyst</LastName>
                    <ForeName>Nicola A</ForeName>
                    <Initials>NA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Endocrinology and Metabolism Unit, Developmental Origins of Health and Disease Division, University of Southampton, Southampton, UK. nae@soton.ac.uk</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Horsfield</LastName>
                    <ForeName>Gill</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kwan</LastName>
                    <ForeName>Joseph</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Byrne</LastName>
                    <ForeName>Christopher D</ForeName>
                    <Initials>CD</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2008</Year>
                <Month>03</Month>
                <Day>05</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Cereb Blood Flow Metab</MedlineTA>
            <NlmUniqueID>8112566</NlmUniqueID>
            <ISSNLinking>0271-678X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>R16CO5Y76E</RegistryNumber>
                <NameOfSubstance UI="D001241">Aspirin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001241">Aspirin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020520">Brain Infarction</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004351">Drug Resistance</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004617">Embolism</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015850">Interleukin-6</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015539">Platelet Activation</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020521">Stroke</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2008</Year>
                <Month>3</Month>
                <Day>05</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2008</Year>
                <Month>3</Month>
                <Day>6</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2008</Year>
                <Month>7</Month>
                <Day>19</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2008</Year>
                <Month>3</Month>
                <Day>6</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">jcbfm20089</ArticleId>
            <ArticleId IdType="doi">10.1038/jcbfm.2008.9</ArticleId>
            <ArticleId IdType="pubmed">18319729</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">12195138</PMID>
        <DateCreated>
            <Year>2002</Year>
            <Month>08</Month>
            <Day>26</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2002</Year>
            <Month>12</Month>
            <Day>04</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1095-0680</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>18</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2002</Year>
                        <Month>Jun</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The journal of ECT</Title>
                <ISOAbbreviation>J ECT</ISOAbbreviation>
            </Journal>
            <ArticleTitle>ECT treatment of malignant catatonia/NMS in an adolescent: a useful lesson in delayed diagnosis and treatment.</ArticleTitle>
            <Pagination>
                <MedlinePgn>95-8</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>A 17-year-old adolescent female presented to a psychiatric emergency room with excitement, confusion, and psychotic symptoms. After brief exposure to haloperidol and olanzapine, she developed fever, rigidity, waxy flexibility, autonomic instability, and elevated creatinine phosphokinase enzyme. Approximately 6 weeks after the onset of the illness, multiple laboratory tests, and evaluation at three different hospitals, the condition was effectively treated with electroconvulsive therapy (ECT). This case is a lesson in delayed recognition and the delayed use of ECT for the malignant catatonia/neuroleptic malignant syndrome.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ghaziuddin</LastName>
                    <ForeName>Neera</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Child and Adoloscent Psychiatry, University of Michigan, Ann Arbor, Michigan 48109-0390, USA. neerag@umich.edu</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Alkhouri</LastName>
                    <ForeName>Iyad</ForeName>
                    <Initials>I</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Champine</LastName>
                    <ForeName>Donna</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Quinlan</LastName>
                    <ForeName>Paul</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fluent</LastName>
                    <ForeName>Thomas</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ghaziuddin</LastName>
                    <ForeName>Mohammad</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J ECT</MedlineTA>
            <NlmUniqueID>9808943</NlmUniqueID>
            <ISSNLinking>1095-0680</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>12794-10-4</RegistryNumber>
                <NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>132539-06-1</RegistryNumber>
                <NameOfSubstance UI="C076029">olanzapine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>3G0285N20N</RegistryNumber>
                <NameOfSubstance UI="D010890">Pirenzepine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>J6292F8L3D</RegistryNumber>
                <NameOfSubstance UI="D006220">Haloperidol</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001569">Benzodiazepines</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001921">Brain</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002389">Catatonia</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003937">Diagnosis, Differential</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003952">Diagnostic Imaging</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D004565">Electroconvulsive Therapy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004569">Electroencephalography</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006220">Haloperidol</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009459">Neuroleptic Malignant Syndrome</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009460">Neurologic Examination</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009483">Neuropsychological Tests</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010890">Pirenzepine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2002</Year>
                <Month>8</Month>
                <Day>27</Day>
                <Hour>10</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2002</Year>
                <Month>12</Month>
                <Day>5</Day>
                <Hour>4</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2002</Year>
                <Month>8</Month>
                <Day>27</Day>
                <Hour>10</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12195138</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
